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Abstract: 
 
Recent findings suggest that treatment with 11β-HSD1 inhibitors provides a novel 
approach to deal with age-related cognitive dysfunctions, including Alzheimer’s 
disease. In this work we report potent 11β-HSD1 inhibitors featuring unexplored 
pyrrolidine-based polycyclic substituents. A selected candidate administered to 12-
month-old SAMP8 mice for four weeks prevented memory deficits and displayed a 
neuroprotective action. This is the first time that 11β-HSD1 inhibitors have been studied 
in this broadly-used mouse model of accelerated senescence and late-onset Alzheimer’s 
disease.  
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Keywords: 
Glucocorticoids, 11β-HSD1 inhibitors, drug design, adamantane, polycyclic 
substituents, aged-related cognitive dysfunction, Alzheimer’s disease, SAMP8 mouse. 
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Highlights: 
 
a) Several pyrrolidine-based polycyclic amides are prepared as 11β-HSD1 
inhibitors. 
b) Amides are synthesized by coupling of pyrrolidines with carboxylic acids. 
c) The more potent compounds present low nanomolar IC50. 
d) A candidate is administered to old SAMP8 mice for four weeks. 
e) The treatment prevents memory deficits and displays a neuroprotective action. 
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1. Introduction 
Elevated glucocorticoids (GCs) exposure is widely accepted as a key factor in age-
related cognitive decline in rodents and humans [1-3]. High levels of GCs have been 
found in elderly individuals who exhibit learning and memory impairments. GC levels 
correlate with greater hippocampal atrophy, a region of the brain that is crucial for 
memory formation [3]. In contrast, low GC levels achieved through neonatal 
programming or adrenalectomy with exogenous steroid replacement in rats results in the 
prevention of memory impairments with aging [4]. 
Growing evidence also suggests that excessive glucocorticoid activity may contribute to 
Alzheimer’s disease (AD), since elevated levels of circulating cortisol in AD patients 
are associated with more rapid disease progression [5-6]. In a rodent model of AD, 
systemic administration of GCs led to increases in β-amyloid and tau pathology, the two 
major histopathologic hallmarks of AD, suggesting a relationship between elevated GC 
levels and AD pathology [7]. Overall, these data suggest that reducing GC levels in the 
brain may relieve cognitive dysfunction in both aging and AD. 
As in other tissues, the presence of GCs in the brain is not only dependent on adrenal 
secretion and diffusion from the circulation but also on intracellular metabolism [8]. 
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes the regeneration of 
active GCs (cortisol in humans, corticosterone in rodents) from their inactive forms 
(cortisone and 11-dehydrocorticosterone, respectively), providing a local amplification 
of GC action [9-10]. 11β-HSD1 is highly expressed in fundamental brain areas for 
cognition, such as the hippocampus, cortex and amygdala [11-13]. By contrast, the 
isoenzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), which catalyzes the 
opposite reaction, plays an important role during development, as expression of 11β-
HSD2 is relevant in fetal brain and placenta, but it has very limited expression in the 
adult brain [14-16]. 
Recent studies have demonstrated that aged mice with cognitive deficits show increased 
11β-HSD1 expression in the hippocampus and forebrain, and that overexpression of 
11β-HSD1 leads to a similar premature memory decline [17]. Conversely, 11β-HSD1 
knock-out mice and even heterozygous null mice performed better in different 
behavioral tests, which suggests resistance to cognitive decline due to a neuroprotective 
effect of 11β-HSD1 inhibition [18]. Accordingly, this protection correlates with loss of 
the age-associated rise in intrahippocampal corticosterone, insinuating a role for 11β-
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HSD1 in maintaining plasma corticosterone concentration [17]. Furthermore, acute and 
short-term treatments with 11β-HSD1 inhibitors have shown memory consolidation and 
improvements in cognitive function in aged mice and AD models [19-23]. Altogether, 
these findings suggest that 11β-HSD1 inhibitors provide a novel approach through a 
non-cholinergic mechanism to deal with these cognitive disorders. 
In the present work, we report the results derived from a synthetic strategy, supported by 
molecular modeling studies, designed towards a novel family of potent 11β-HSD1 
inhibitors, featuring unexplored pyrrolidine-based polycyclic substituents. The more 
potent compounds were characterized in terms of cellular potency, isoenzyme 
selectivity, human metabolic stability and predicted brain penetration to select a 
candidate for an in vivo study. For the first time in the context of 11β-HSD1 inhibitors, 
the Senescence Accelerated Mouse-Prone 8 (SAMP8) mice were used, as a naturally 
occurring mouse strain that displays a phenotype of accelerated aging as observed in 
AD and widely used as a robust rodent model of cognitive dysfunction [24-25]. 
 
2. Design, synthesis and in vitro evaluation of new inhibitors 
Given that the 11β-HSD1 active site includes a hydrophobic pocket that can 
accommodate bulky lipophilic substituents, the introduction of a lipophilic group, such 
as adamantyl, has proven a successful strategy for the space filling of the cavity. Thus, 
several adamantyl-containing 11β-HSD1 inhibitors exhibit high affinity and potency 
and some of them (e.g. AZD8329 and ABT-384) have reached clinical trials (Figure 1) 
[26-34]. Although the evaluation of alternative polycyclic hydrocarbons may offer 
further opportunities for optimizing the space filling of the hydrophobic cavity, the use 
of other polycyclic substituents featuring different size or shape has only been briefly 
scrutinized (e.g. AMG-221 and MK-0736) [35-36].  
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Figure 1. Selected 11β-HSD1 inhibitors. 
 
In the last few years, our research group has investigated new polycyclic substituents as 
surrogates of the adamantyl group, leading to inhibitors with promising results on 
multiple targets [37-45]. However, this strategy has not been successful yet in the case 
of human 11β-HSD1 inhibitors [46]. Very recently, we have found that the N-(2-
adamantyl)amide derivatives 1 and 2 (Figure 2), which are achiral analogues of PF-
877423 (IC50 = 4 nM) [47], are potent inhibitors of 11β-HSD1 (IC50 = 86 and 74 nM, 
respectively) [48]. Interestingly, the corresponding urea analog, 3, was significantly less 
potent (IC50 = 873 nM) [48]. Taking into account the simplicity of these three right-hand 
side (RHS) units, here we initially selected these fragments for finding alternative 
polycyclic substituents able to successfully replace the adamantyl group in 11β-HSD1 
inhibitors. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 of 52 
 
 
Figure 2. PF-877423 and related inhibitors. 
 
The design of new inhibitors was initially based on a structure-activity relationship 
(SAR) investigation we previously adopted [46]. The structure of the putative inhibitor 
was partitioned into two parts: the polycyclic substituent, a surrogate of adamantyl, and 
the carbocyclic or heterocyclic ring, linked by an amido or urea unit, respectively. Since 
inspection of the available X-ray structures and preliminary docking studies (see below) 
indicated that the enzyme active site is large enough to accommodate a polycycle bigger 
than adamantane, we started our endeavour with previously synthesized amines 4, 5 and 
10, three compounds that were successfully used to replace 1-adamantylamine in other 
targets (Scheme 1) [38]. These amines were then combined with a common RHS moiety 
to shed light on the effect of key structural features on the inhibitory action: i) primary 
vs secondary amine (e.g. 4 vs 10), ii) distance between the polycyclic ring and the 
nitrogen atom (e.g. 4 vs 5), iii) restraint of the conformational freedom (e.g. 5 vs 10), 
and iv) by incorporating two double bonds in the polycycle, which might form 
additional interactions in the binding site (e.g. derivatives of 10 vs its reduced 
analogues). Amides 6 and 7 were prepared in high yields by reaction of cyclohexane 
acyl chloride with amines 4 and 5, respectively. From amine 10, using either 
cyclohexanecarboxylic acid or 4-amino-3,5-dichlorobenzoic acid in combination with 
1-hydroxybenzotriazole (HOBt) and N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
(EDC) amides 11 and 15 were synthesized in moderate yields. Ureas 8, 9 and 13 were 
prepared from the required amine and N-chloroformylpiperidine in moderate to 
excellent yields. Finally, catalytic hydrogenation of 11, 13 and 15 furnished 12, 14 and 
16, respectively (Scheme 1). 
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Scheme 1. Amines 4, 5 and 10, and amides and ureas derived thereof. a 
aReagents and conditions: (i) cyclohexanecarbonyl  chloride, anh. acetone, reflux, 3 h, 
95% yield for 6; 78% yield for 7; (ii) 1-piperidinecarbonyl chloride, Et3N, DCM, rt, 
overnight, 54% yield for 8; quant yield for 9; 71% for 13; (iii) cyclohexanecarboxylic 
acid for 11 or 4-amino-3,5-dichlorobenzoic acid for 15, HOBt, EDC, Et3N, EtOAc, rt, 
overnight, 42% yield for 11; 47% yield for 15; (iv) H2, Pd/C, abs. EtOH, rt, 5 h for 12 
and 16, 3 h for 14, 78% yield for 12; 72% yield for 14; 89% yield for 16. 
 
A preliminary in vitro microsomal assay at 10 µM compound concentration was 
performed to assess if the synthesized compounds were able to inhibit human 11β-
HSD1, and the IC50 values were determined for those compounds presenting an 
inhibition higher than 50% (Table 1). 
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Compound hHSD1 % inh at 10 µM hHSD1 IC50 (µM) 
6 41 ND 
7 28 ND 
8 50 ND 
9 50 ND 
11 95 1.08 
12 100 0.29 
14 100 0.32 
15 98 2.77 
16 98 0.41 
Table 1. 11β-HSD1 inhibition by compounds 6-9, 11, 12 and 14-16. a,b  
a11β-HSD1 inhibition was determined in mixed sex, human liver microsomes (Celsis 
In-vitro Technologies) by measuring the conversion of 3H-cortisone to 3H-cortisol in a 
cortisol-scintillation proximity assay. bPercentage inhibition was determined relative to 
a control system in the absence of inhibitor (see Experimental section for further 
details). ND, not determined. 
 
The analysis of the inhibitory potencies disclosed some SAR. First, while amides 6 and 
7 displayed poor inhibitory activity, derivatives 11 and 12, featuring a pyrrolidine ring, 
showed low micromolar and submicromolar potency, respectively, reflecting a better fit 
within the hydrophobic pocket of the binding site. Second, replacement of the 
cyclohexyl ring of 12 by either a 1-piperidinyl substituent, as in 14, or a 4-amino-3,5-
dichlorophenyl group, as in 16, retained the activity, further demonstrating that the 
adamantyl substituent may be replaced by other polycyclic groups. Third, no significant 
difference was found between the inhibitory activity of 12 and 14, and hence the 
replacement of the amide bridge by a urea within this particular polycycle does not 
seem to affect the potency. Finally, saturated hexacyclic pyrrolidines were more potent 
than their diene analogues (compare 12 vs 11 and 16 vs 15). Overall, aliphatic amides 11 
and 12 were slightly more potent than aromatic amides 15 and 16 (compare 11 vs 15 
and 12 vs 16). 
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Figure 3. Representative snapshot of the binding mode of compounds 12 (A), 14 (B), 8 
(C), and 23 (D) to the human 11β-HSD1 enzyme as determined from the analysis of the 
MD simulations. The protein backbone is shown as blue carton, the NADP cofactor, 
residues Tyr183 and Ser170, and the ligands are shown as atom-coloured sticks. The 
hydrogen bond between the ligand and the hydroxyl group of Ser170 is shown as a 
dashed line. 
Docking studies were combined with molecular dynamics (MD) simulations to shed 
light into the inhibitory potencies of selected compounds. The structural integrity of the 
simulated systems was supported by the stability of the positional root-mean square 
deviation of the residues that define the binding site and the ligand, especially for the 
most potent compounds (see Figures S1-S3 in Supporting Information). A similar 
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binding mode was found for compounds 8, 12 and 14 (see Figure 3). In all cases the 
carbonyl group of the ligand formed a stable hydrogen bond with Ser170 (distances 
ranging from 2.6 to 3.0 Å). However, the hydrogen bond of the ligand’s carbonyl group 
with the hydroxyl group of Tyr183, which was retained during the setup of the 
simulated systems, exhibited larger fluctuations and was eventually disrupted during the 
trajectories. Docking calculations showed compounds 12 and 14 to have slightly better 
scores (-9.3 and -9.7 kcal/mol, respectively) than for 6 (-8.4 kcal/mol) and 8 (-9.0 
kcal/mol). The higher inhibitory potency of 12 and 14 may also be explained by the 
fused pyrrolidine ring, which should reduce the contribution of the conformational 
penalty to the binding affinity of these compounds compared to the more flexible 
compounds 6 and 8. Although the results appear to support the ability of the size-
expanded hydrophobic cage present in 12 and 14 to occupy the binding pocket, the 
lower inhibitory potency compared to 1 (IC50 = 86 nM; Figure 2) suggests that the size 
of the polycyclic substituent in 12 and 14 may be close to the upper limit allowed for 
ligand binding without triggering significant structural distortions in the pocket 
Of note, the N-acylpyrrolidine motif contained in 11, 12, 15 and 16 has scarcely been 
explored in the context of the design of 11β-HSD1 inhibitors [49]. However, the 
pyrrolidine 10 is not an ideal starting compound for a medicinal chemistry program, as 
its synthesis is tedious and very low-yielding [38]. For this reason, we explored the 
synthesis of alternative, easily synthesized, pyrrolidine derivatives. To this end, we 
followed a polycyclic substituent optimization process in which the cyclohexyl was 
selected as the RHS of the molecule, due to its simplicity (i.e. achiral, easy access) and 
good performance with both adamantyl (1, IC50 = 0.09 µM) and hexacyclic substituents 
(12, IC50 = 0.29 µM). An array of 13 pyrrolidine-based polycyclic amides was prepared 
from cyclohexanecarboxylic acid, HOBt, EDC, and a series of previously synthesized 
amines (Figure 4). Our aim was to obtain different pyrrolidine-based polycyclic 
compounds, some of them simplified analogs of the hexacyclic unit contained in 10 but 
with higher conformational freedom, in order to find the optimal size and shape to 
deliver more potent 11β-HSD1 inhibitors. 
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Figure 4. Novel pyrrolidine-based polycyclic amides 17-29. 
 
Following the aforementioned preliminary in vitro microsomal assay, the IC50 values 
were determined for compounds with an inhibitory activity higher than 50% at 10 µM 
(Table 2). In general, compounds containing smaller polycyclic rings (i.e. 17-23) were 
one order of magnitude more potent than our initially best inhibitors 12, 14 and 16, and 
some of them were also more potent than the adamantyl derivative 1 (IC50 = 0.09 µM). 
The most potent inhibitors were 18, 20, 21, 22 and 23 (IC50 values ranging from 0.02 to 
0.03 µM). MD simulations of the enzyme complex with compound 23 confirmed the 
stability of the binding mode (see Figure 3D and S4), which resembled the arrangement 
of compound 12, and the formation of the hydrogen-bond interaction with Ser170 
(average distance of 2.8 ± 0.3 Å). However, there was not a clear trend in terms of 
activity between the alkene/alkane pairs containing the same polycyclic ring system 
(compare 20 vs 21, and 22 vs 23). Thus, in the pair 18/19 the alkene derivative 
presented a slightly higher potency, but the bigger alkene derivatives 24 and 26 were 
significantly more potent than their alkane analogues 25 and 27 (IC50 = 1.49 µM vs 27% 
inhibition at 10 µM, and 0.04 µM vs 1.22 µM, respectively). Finally, the introduction of 
four methyl groups, either in an extended (28) or compact (29) arrangement, was highly 
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deleterious to the inhibitory activity (compare 26 vs 28 and 29). Overall, these findings 
reinforce the assumption that the hexacyclic substituent reaches the upper-limit size to 
fill the hydrophobic pocket of the binding site. 
 
Compound hHSD1 % inh at 10 µM hHSD1 IC50 (µM) 
17 85 0.05 
18 89 0.02 
19 92 0.09 
20 96 0.03 
21 95 0.02 
22 100 0.02 
23 100 0.03 
24 83 1.49 
25 27 ND 
26 82 0.04 
27 67 1.22 
28 30 ND 
29 42 ND 
Table 2. 11β-HSD1 inhibition by compounds 17-29.a,b 
a11β-HSD1 inhibition was determined in mixed sex, Human Liver Microsomes 
(Celsis In-vitro Technologies) by measuring the conversion of 3H-cortisone to 3H-
cortisol in a cortisol-Scintillation Proximity Assay. bPercentage inhibition was 
determined relative to a no inhibitor control (see Experimental section for further 
details). ND, not determined. 
 
3. Biological profiling of the more potent 11β-HSD1 inhibitors 
The more potent inhibitors obtained by this polycyclic substituent optimization process 
have clogP values between 2.68 and 3.99, more desirable than that of the adamantyl-
containing analogue 1 (clogP = 4.65).  These new compounds were characterized in 
terms of cellular potency, selectivity over 11β-HSD2, human metabolic stability, 
cytochromes P450 (CYP) inhibition and predicted brain permeability, in order to select 
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the best candidate to perform an in vivo study in a rodent model of cognitive 
dysfunction. 
The cellular potency was assessed in Human Embryonic Kidney 293 (HEK293) cells 
stably transfected with the 11β-HSD1 gene. With the only exception of alkenes 18, 20 
and 26, which showed a moderate inhibitory activity (55%, 64% and 64%, 
respectively), all compounds completely inhibited the enzyme at 10 µM (Table 3).  
Selectivity over 11β-HSD2 is required for 11β-HSD1 inhibitors progressing into clinical 
trials since 11β-HSD2 inhibition in the kidney can lead to sodium retention and 
increased blood pressure via cortisol stimulation of mineralocorticoid receptors. 
However, for the purposes of our in vivo studiy of cognitive dysfunction in rodents, high 
selectivity vs 11β-HSD2 was not required. Notwithstanding, 11β-HSD2 inhibition was 
assessed in a cellular assay with HEK293 cells stably transfected with the 11β-HSD2 
gene at 10, 1 and 0.1 µM in order to establish the selectivity of our compounds. Ideally, 
the 11β-HSD2 inhibition at 10 µM should be lower than 50% to consider a compound 
sufficiently selective toward 11β-HSD1. None of our compounds achieved this 
threshold but some slightly improved the poor selectivity of the adamantyl-containing 
analogue 1, such as amide 22 (88% vs 69% inhibition at 10 µM, respectively, data not 
shown). Although 22 had an IC50 between 1 and 10 µM, so we cannot rigorously 
consider this compound to be selective against 11β-HSD1, its selectivity index was at 
least 50-fold compared to compounds 20 and 21, which displayed selectivities less than 
5-fold. Poor selectivity was observed for compounds 18, 19 and 23. 
Microsomal stability was performed in human liver microsomes (HLM), which are 
widely used to determine the likely degree of primary metabolic clearance in the liver. 
Compounds 18, 19 and 20 presented moderate microsomal stabilities between 36 and 
60% of remaining parent compound after 30 min incubation, while amides 21 and 22 
showed stabilities lower than 28%. Compound 23 displayed a high microsomal stability 
with 94% of remaining parent compound after the 30 min incubation period. 
The active compounds in the 11β-HSD1 cellular assay (19 and 21-23) were further 
tested for predicted brain permeation using the widely used in vitro PAMPA-BBB 
model [50]. Unfortunately, the in vitro permeabilities (Pe) for compounds 21 and 22 
could not be determined due to their lack of UV absorption. Whereas 19 showed an 
uncertain BBB permeation [CNS ± with 5.179 > Pe (10-6 cm s-1) > 2.106], compound 23 
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had Pe clearly above the threshold established for a high blood-brain barrier (BBB) 
permeation (Pe > 30 x 10-6 cm s-1). 
 
Compound hHSD1 
IC50 
(µM) 
HEK 
hHSD1 % 
inh at 10 
µMc 
HEK hHSD2 
inhibition at 10 
µM or IC50 (µM)c 
HLM % 
parentd 
PAMPA-
BBB 
Pe (10-6 cm 
s-1)e,f 
1 0.09 100 88% 79 - 
18 0.02 55 < 0.1 µM 60 - 
19 0.099 
100 
< 0.1 µM 37 5.20 ± 0.1 
(CNS±) 
20 0.03 64 0.1-1 µM 44 - 
21 0.02 100 0.1-1 µM 17 NDg 
22 0.02 100 1-10 µM 27 ND 
23 0.03 
100 
< 0.1 µM 94 >30 
(CNS+) 
26 0.04 64 100% - - 
Table 3. Biological profiling of the most potent compounds.a,b 
aSee Experimental section for further details. bPercentage inhibition was determined 
relative to a no inhibitor control. cHEK293 cells stably transfected with the full-length 
gene coding for human either 11β-HSD1 or 11β-HSD2 were used. dThe microsomal 
stability of each compound was determined using human liver microsomes. 
ePermeability values from PAMPA-BBB assay. Values are expressed as the mean ± SD 
of three independent experiments. CNS+, predicted positive brain penetration. 
fCalibration line between 0 and 30 x 10-6 cm s-1. gND, not detected. 
 
4. In vivo study 
Recent studies in rodents and humans with brain-penetrant 11β-HSD1 inhibitors have 
shown that they provide beneficial effects on the cognitive impairment associated with 
aging [13, 18-23]. SAMP8 has been studied as a non-transgenic murine mouse model of 
accelerated senescence and late-onset AD [51-52]. These mice exhibit cognitive and 
emotional disturbances, probably due to early development of brain pathological 
hallmarks, such as oxidative stress (OS), inflammation, and activation of neuronal death 
pathways, which mainly affect cerebral cortex and hippocampus [24,53]. To date, this 
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rodent model has not been used to test 11β-HSD1 inhibitors, being this work the first 
investigation of the effects of 11β-HSD1 pharmacological inhibition in SAMP8. 
The in vivo study was performed with amide 23, as this compound had low nanomolar 
potency against the murine 11β-HSD1 enzyme (mHSD1, IC50 = 0.08 µM), high cellular 
potency, high microsomal stability (both in human and mouse liver microsomes, 94 and 
93%, respectively) and positive predicted brain penetration. A pharmacokinetic study of 
compound 23 was performed in order to assess its oral administration. Although its 
clearance seems to be rapid, the concentration levels at 30 min post-administration are 
five fold the IC50 (Table S1, Figure S5 and Table S2). In addition, we could also 
measure compound concentration in brain tissue at 3 hours post-administration (1.45 
ng/mL), hint of in vivo BBB permeability. Then, compound 23 was administered to 12-
month-old SAMP8 mice in drinking water during four weeks at a concentration of 105 
mg/L (average body weight for 48-week-old mice is 25 g; fluid consumption is 5 mL, 
therefore the dose was 0.105 mg/mL x 5 mL/0.025 kg = 21 mg/kg). Compound 23 was 
dissolved in polyethylene glycol 400 (PEG400) and then diluted with water to a 
PEG400 final concentration of 2% (v/v) in drinking fluid. 2% PEG400 in water was 
given to the remaining mice in drinking fluid as a vehicle control. 
Neuroprotective effects were investigated through a behavioural test, the novel object 
recognition test (NORT), as a common measure of cognition (short-term and long-term 
memory) [54], and biochemical analysis, which were made through Western blotting 
and quantitative real-time polymerase chain reaction (qPCR). Brain tissue was analysed 
upon termination of the study to determine compound levels and ex vivo inhibition of 
11β-HSD1. Consistent with previous reports, we found that aged SAMP8 mice 
presented memory impairments in the NORT when compared to young animals [53]. 
Satisfactorily, treatment with 23 certainly prevented short-term and long-term memory 
deficits in SAMP8 mice (Figure 5A).  
Postsynaptic density 95 (PSD95) protein levels were evaluated as a measure of neuronal 
synapses, whereas gene expression for interleukin-6 (IL-6), which acts as a pro-
inflammatory cytokine, and for inducible nitric oxide synthase (iNOS), an oxidative 
stress sensor that catalyzes the production of nitric oxide (NO), were also studied. 
Treatment with 23 prevented the reduction of PSD95 protein levels, while the oxidative 
stress and pro-inflammatory gene expression markers, such as iNOS and IL-6, were 
significantly decreased compared to untreated mice (Figure 5A-B). These observations 
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indicate a neuroprotective action of 23, whereby reduced cognitive impairment in 23-
treated mice is mediated by a reduction of neuroinflammation and oxidative stress as 
confirmed by in the measurements of pro-inflammatory biomarkers (IL-6 and iNOS). 
AD is characterized by the production and deposition of β-amyloid and it has been 
postulated that its reduction produces beneficial effects [55]. For these reasons, the 
effect of 23 in modifying amyloid processing pathways was also examined. No changes 
in amyloid beta A4 precursor (PreAPP), β-secretase 1 (Bace1), disintegrin and 
metalloproteinase 10 (Adam 10) gene expression levels were found (data not shown). 
Nevertheless, after treatment with 23, we found a decrease of APP β-secretase C-
terminal fragment (βCTF) protein levels without modification of those of PreAPP, 
together with an increase of the protein levels of insulin-degrading enzyme (IDE) 
(Figure 1C), a zinc metalloprotease that degrades β-amyloid species. Several in vitro 
and in vivo studies have shown correlations between IDE, β-amyloid levels and AD 
[56].  
In an attempt to elucidate the mechanisms underlying the beneficial effects of 23 and 
the relationship with cognitive amelioration in old SAMP8, we focused our study on 
amyloid processing and βCTF because of its implication in neurodegeneration and 
cognitive decline process in this strain [57]. Amide 23 did not alter the 
proamiloidogenic pathway in SAMP8, as demonstrated by the lack of effect on Pre-
APP, Adam10 or Bace1 gene expression (see Figure S6 in the Supplementary material 
file). However, the capacity of the brain to remove proamiloidogenic species by 
activation of specific proteases, such as IDE or neprilysine, appeared greatly increased 
in treated SAMP8 with higher protein levels of IDE than in control animals and 
consequently with substantially decreased βCTF protein levels. The results of the 
behavioural and biochemical studies in SAMP8 mice suggest that compound 23 acts 
centrally on 11β-HSD1.  
Overall, behavioural tests and biochemical analyses confirmed a neuroprotective action 
of compound 23, probably by reduction of inflammation and oxidative stress, as 
measured by reduction of IL-6 and iNOS. 
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Figure 5. Results of in vivo study. 2A. -Cognition and synaptic density: -Left panel: 
Results. Discrimination index of Novel Object recognition test (NORT) obtained in 
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young SAMP8, old SAMP8 and treated SAMP8, at 2 and 24 h. -Right Panel: 
Representative Western blot (wb) for PSD95 and quantification. 2B. -Oxidative stress 
and inflammation: -Left Panel: Oxidative stress gene expression iNOS. -Right panel: 
pro-inflammatory gene expression for IL-6. Gene exprexion levels were determined by 
real-time PCR. 2C. -Amyloid processing and β-CTF clearance: -Left panel: 
Representative Western blot (wb) for IDE and quantification. -Right panel: 
Representative Western blot (wb) for Pre-APP and β-CTF and β-CTF/APP ratio 
quantification. For Western blot, bars represent mean ± standard error of the mean 
(SEM), and values are adjusted to 100% for levels SAMP8 young. For real-time PCR, 
mean ± SEM from five independent experiments performed in triplicate are represented. 
The One-Way ANOVA analysis and Tukey post hoc analysis were conducted. 
Statistical outliers (Grubbs' test) were removed from the analyses. *p<0.05; **p<0.01; 
***p<0.001. 
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5. Conclusions 
We have found that adamantyl, widely used as a lipophilic substituent in 11β-HSD1 
inhibitors, may successfully be replaced by other polycyclic hydrocarbons. The 
previously scarcely explored pyrrolidine-based polycyclic substituents presented here 
led to potent 11β-HSD1 inhibitors, and potentially these aliphatic ring-systems can 
serve as alternatives to adamantyl. Of note, the novel nanomolar inhibitors reported are 
achiral and easily synthesized in maximum four synthetic steps (compounds 19, 21 and 
23) from commercially available starting materials. Biological profiling allowed us to 
select amide 23 for the first in vivo study in SAMP8 aiming to investigate the 
pharmacological effects of 11β-HSD1 inhibition in this model of cognitive dysfunction. 
In this study, prevention of cognitive impairment in aged SAMP8 after four-week 
treatment with 23 was demonstrated in comparison with control animals. The results 
provide further support for the neuroprotective effect of 11β-HSD1 inhibition, through 
reduction of neuroinflammation and oxidative stress, in cognitive decline related to the 
aging process. Due to the promising biological activity of 23, further optimization is 
currently being carried out, with focus on modifying the RHS of the molecule to 
improve the selectivity and DMPK properties. 
6. Experimental section 
6.1. Chemistry 
6.1.1.  General 
Melting points were determined in open capillary tubes with a MFB 595010M 
Gallenkamp. 400 MHz 1H/100.6 MHz 13C NMR spectra, and 500 MHz 1H NMR 
spectra were recorded on Varian Mercury 400, and Varian Inova 500 spectrometers, 
respectively. The chemical shifts are reported in ppm (δ scale) relative to internal 
tetramethylsilane, and coupling constants are reported in Hertz (Hz). Assignments given 
for the NMR spectra of the new compounds have been carried out on the basis of 
DEPT, COSY 1H/1H (standard procedures), and COSY 1H/13C (gHSQC and gHMBC 
sequences) experiments. IR spectra were run on Perkin-Elmer Spectrum RX I 
spectrophotometer. Absorption values are expressed as wave-numbers (cm−1); only 
significant absorption bands are given. Column chromatography was performed either 
on silica gel 60 Å (35−70 mesh) or on aluminium oxide, neutral, 60 Å (50-200 µm, 
Brockmann I). Thin-layer chromatography was performed with aluminum-backed 
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sheets with silica gel 60 F254 (Merck, ref 1.05554), and spots were visualized with UV 
light and 1% aqueous solution of KMnO4. The analytical samples of all of the new 
compounds which were subjected to pharmacological evaluation possessed purity ≥95% 
as evidenced by their elemental analyses.  
6.1.2.   General procedures for the synthesis of  the compounds 
6.1.2.1.  General procedure A. 
A solution of cyclohexane acyl chloride (1.2 mmol) in anhydrous acetone was added 
to a solution of the amine hydrochloride (1 mmol) and triethylamine (2 mmol) in 
anhydrous acetone. The reaction mixture was stirred at 90º C for 3 h. The resulting 
residue was dissolved with DCM (20 mL) and washed with 1 M aqueous solution of 
HCl (4 x 25 mL), dried over anh. Na2SO4 and filtered. The evaporation in vacuo of the 
organics gave the desired product. 
6.1.2.2.  General procedure B. 
To a solution of the amine hydrochloride (1 mmol) in DCM (10 mL) were added 1-
piperidinecarbonyl chloride (1.5 mmol) and triethylamine (4 mmol). The reaction 
mixture was stirred at rt overnight. To the resulting mixture was added saturated 
aqueous solution of NaHCO3 (10 mL) and the phases were separated. The aqueous layer 
was extracted with further DCM (2 x 10 mL). The organics were washed with 10% 
Na2CO3 solution (30 mL), dried over anh. Na2SO4, filtered and concentrated in vacuo to 
give the desired product. 
6.1.2.3.  General procedure C. 
To a solution of amine hydrochloride (1.1 mmol) in EtOAc (15 mL) were added the 
carboxylic acid (1 mmol), HOBt (1.5 mmol), EDC (1.5 mmol) and triethylamine (4 
mmol) and the reaction mixture was stirred at rt overnight. To the resulting suspension 
was then added water (15 mL) and the phases were separated. The organic phase was 
washed with saturated aqueous NaHCO3 solution (15 mL) and brine (15 mL), dried 
over anh. Na2SO4 and filtered. The organic layer was concentrated in vacuo to give the 
desired product. 
6.1.2.4.  General procedure D. 
A solution or suspension of the amide or urea (1 mmol) and 5 wt. % palladium on 
carbon (50% in water, 10% of the weight) in absolute ethanol (ca 30 mL) was stirred at 
rt and atmospheric pressure under hydrogen for 3-72 h. The suspension was then 
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filtered and the solids were washed with EtOH (10 mL). The solvents were removed in 
vacuo to give the desired reduced product. 
6.1.3.  N-[Pentacyclo[6.4.0.02 ,1 0 .03 ,7 .04 ,9]dodec-8-yl]  
cyclohexanecarboxamide, (6).  
From cyclohexane acyl chloride (128 mg, 0.88 mmol) in anhydrous acetone (0.6 mL) 
and amine 4 [38] (152 mg, 0.72 mmol) and triethylamine (0.25 mL, 1.74 mmol) in 
anhydrous acetone (0.9 mL) and following the general procedure A, amide 6 (215 mg, 
95% yield) was obtained as a yellow solid. The analytical sample was obtained by 
crystallization from EtOAc / pentane (164 mg), mp 228 ̶ 229 ºC; IR (ATR) ν: 580, 591, 
604, 638, 663, 695, 722, 761, 824, 894, 933, 1143, 1194, 1221, 1277, 1304, 1336, 1386, 
1448, 1547, 1639, 2851, 2923, 3271 cm-1; 1H-NMR (400 MHz, CDCl3) δ: 1.08 (t, J = 
2.8 Hz, 1 H, 9’-H), 1.18-1.34 [complex signal, 3 H, 3(5)-Hax and 4-Hax], 1.39-1.55 
[complex signal, 10 H, 5’(11’)-H2, 6’(12’)-H2 and 2(6)-Hax], 1.66 (m, 1 H, 4-Heq), 1.79 
[m, 2 H, 3(5)-Heq], 1.85 [m, 2 H, 2(6)-Heq], 2.08 (tt, J = 11.6 Hz, J’ = 3.4 Hz, 1 H, 1-H), 
2.13 [b. s., 2 H, 4’(10’)-H], 2.21 [m, 2 H, 2’(3’)-H], 2.81 [b. s., 2 H, 1’(7’)-H], 5.47 (s, 1 
H, NH); 
13C-NMR (100.5 MHz, CDCl3) δ: 21.5 [CH2, C5’(C11’)], 24.4 [CH2, 
C6’(C12’)], 25.7 (CH2, C4), 25.8 [CH2, C3(5)], 30.1 [CH2, C2(C6)], 45.8 (CH, C1), 
46.9 [CH, C2’(3’)], 52.8 [CH, C4’(10’)], 53.4 [CH, C1’(7’)], 54.8 (CH, C9’), 65.4 (C, 
C8’), 176.7 (C, CO). Anal. Calcd for C19H27NO: C 79.95, H 9.54, N 4.91. Found: C 
79.73, H 9.75, N 4.82. 
6.1.4. N-[[Pentacyclo[6.4.0.02,10.03,7.04,9]dodec-8-yl]methyl]cyclohexanecarboxamide, 
(7). 
From cyclohexane acyl chloride (119 mg, 0.81 mmol) in anhydrous acetone (0.6 mL) 
and amine 5 [38] (150 mg, 0.67 mmol) and triethylamine (0.23 mL, 1.62 mmol) in 
anhydrous acetone (0.8 mL) and following the general procedure A, amide 7 (155 mg, 
78% yield) was obtained as a dark solid. The analytical sample was obtained by 
crystallization from EtOAc / pentane (77 mg), mp  148 ̶ 149 ºC; IR (ATR) ν: 576, 589, 
604, 621, 660, 672, 711, 800, 894, 956, 979, 1037, 1106, 1123, 1180, 1213, 1252, 1298, 
1314, 1380, 1435, 1443, 1550, 1633, 1659, 2855, 2928, 3299 cm-1; 1H-NMR (400 MHz, 
CDCl3) δ: 1.05 (b. s., 1 H, 9’-H), 1.17-1.33 [complex signal, 3 H, 3(5)-Hax and 4-Hax], 
1.35-1.55 [complex signal, 8 H, 5’(11’)-Hexo or endo, 6’(12’)-H2 and 2(6)-Hax], 1.56-1.70 
[complex signal, 3 H, 5’(11’)-Hendo or exo and 4-Heq], 1.74-1.87 [complex signal, 4 H, 
2(6)-Heq and 3(5)-Heq], 1.98 [b. s., 2 H, 4’(10’)-H], 2.05 (tt, J = 11.6 Hz, J’ = 3.2 Hz, 1 
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H, 1-H), 2.13 [b. s., 2 H, 1’(7’)-H], 2.22 [m, 2 H, 2’(3’)-H], 3.38 [d, J = 5.6 Hz, 2 H, 
NCH2], 5.20 [b. s., 1H, NH]; 13C-NMR (100.5 MHz, CDCl3) δ: 22.3 [CH2, C5’(C11’)], 
24.2 [CH2, C6’(12’)], 25.7 (3 CH2, C3, C4 and C5), 29.8 [CH2, C2(6)], 36.9 (CH2, 
NCH2), 42.7 (C, C8’), 45.7 (CH, C1), 47.9 [CH, C2’(3’)], 51.2 (CH, C9’), 53.1 [CH, 
C1’(7’)], 53.5 [CH, C4’(10’)], 175.6 (C, CO). Anal. Calcd for C20H29NO·0.15 EtOAc: 
C 79.13, H 9.74, N 4.48. Found: C 79.03, H 9.88, N 4.52. 
6.1.5. N-[Pentacyclo[6.4.0.02,10.03,7.04,9]dodec-8-yl]piperidine-1-carboxamide, (8). 
From amine 4 [38] (100 mg, 0.47 mmol), 1-piperidinecarbonyl chloride (0.09 mL, 0.71 
mmol) and triethylamine (0.23 mL, 1.88 mmol) in DCM (5 mL) and following the 
general procedure B, amide 8 (72 mg, 54% yield) was obtained as a white solid. The 
analytical sample was obtained by crystallization from hot EtOAc (22 mg), mp 225 ̶ 226 
ºC; IR (ATR) ν: 700, 721, 734, 764, 794, 851, 866, 907, 954, 971, 1003, 1019, 1050, 
1128, 1141, 1187, 1232, 1254, 1261, 1276, 1306, 1325, 1357, 1395, 1440, 1479, 1520, 
1615, 2024, 2158, 2855, 2930, 3362 cm-1; 1H-NMR (400 MHz, CDCl3) δ: 0.99 (broad s, 
1 H, 9’-H), 1.43-1.65 complex signal, 14 H, 5’(11’)-H2, 6’(12’)-H2, 3(5)-H2 and 4-H2], 
2.13 [broad s, 2 H, 4’(10’)-H], 2.21 [broad s, 2 H, 2’(3’)-H], 2.78 [broad s, 2 H, 1’(7’)-
H], 3.31 [m, 4 H, 2(6)-H2], 4.53 (broad s, 1 H, NH); 13C-NMR (100.5 MHz, CDCl3) δ: 
21.5 [CH2, C5’(11’)], 24.5 (CH2, C4), 24.6 [CH2, C6’(12’)], 25.6 [CH2, C3(5)], 45.2 
[CH2, C2(6)], 46.8 [CH, C2’(3’)], 52.8 [CH, C4’(10’)], 53.6 [CH, C1’(7’)], 55.4 (CH, 
C9’), 65.8 (C, C8’), 157.4 (C, CO); HRMS-ESI+ m/z [M+H]+ calcd for 
[C18H26N2O+H]+: 287.2118, found: 287.2118. 
6.1.6. N-[[Pentacyclo[6.4.0.02,10.03,7.04,9]dodec-8-yl]methyl]piperidine-1-carboxamide, 
(9). 
From amine 5 [38] (96 mg, 0.42 mmol), 1-piperidinecarbonyl chloride (0.08 mL, 0.63 
mmol) and triethylamine (0.21 mL, 1.68 mmol) in DCM (5 mL) and following the 
general procedure B, amide 9 (125 mg, quantitative yield) was obtained as a white solid. 
The analytical sample was obtained by crystallization from hot EtOAc (25 mg), mp 144 ̶ 
145 ºC; IR (ATR) ν: 554, 572, 623, 637, 678, 734, 763, 851, 869, 900, 908, 945, 969, 
992, 1023, 1107, 1155, 1232, 1253, 1261, 1340, 1397, 1438, 1451, 1475, 1524, 1614, 
2018, 2158, 2842, 2860, 2930, 3378 cm-1; 1H-NMR (400 MHz, CDCl3) δ: 1.06 (broad s, 
1 H, 9’-H), 1.40-1.70 [complex signal, 14 H, 5’(11’)-H2, 6’(12’)-H2, 3(5)-H2 and 4-H2], 
2.00 [broad s, 2 H, 4’(10’)], 2.13 [broad s, 2 H, 1’(7’)-H], 2.22 [broad s, 2 H, 2’(3’)-H], 
3.28 [m, 4 H, 2(6)-H2], 3.37 (d, J = 5.2 Hz, 2 H, NCH2), 4.18 (broad s, 1H, NH); 13C-
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NMR (100.5 MHz, CDCl3) δ: 22.4 [CH2, C5’(11’)], 24.3 [CH2, C6’(12’)], 24.4 (CH2, 
C4), 25.6 [CH2, C3(5)], 38.6 (CH2, NCH2), 44.5 (C, C8’), 45.0 [CH2, C2(6)], 47.9 [CH, 
C2’(3’)], 51.2 (CH, C9’), 53.1 [CH, C1’(7’)], 53.6 [CH, C4’(10’)], 157.8 (C, CO); 
HRMS-ESI+ m/z [M+H]+ calcd for [C19H29N2O+H]+: 301.2274, found: 301.2276. 
6.1.7. (3-Azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadeca-7,13-dien-3-yl)(cyclohexyl) 
methanone, (11). 
From amine 10 [38] (400 mg, 2.03 mmol), cyclohexanecarboxylic acid (237 mg, 1.85 
mmol), HOBt (375 mg, 2.78 mmol), EDC (430 mg, 2.78 mmol) and triethylamine 
(0.570 mL, 4.07 mmol) in ethyl acetate (30 mL) and following the general procedure C, 
an orange oil (627 mg) was obtained. Column chromatography (Al2O3, DCM/methanol) 
gave amide 11 (260 mg, 42% yield) as a white solid. The analytical sample was 
obtained by crystallization from tert-butanol, mp 111 ̶ 113 ºC; IR (ATR) ν: 2961, 2930, 
2853, 1630, 1443, 1425, 1347, 1305, 1223, 1194, 1138, 1067, 998, 897, 878, 830, 780, 
749, 734, 696, 659, 646 cm-1; 1H-NMR (500 MHz, CDCl3) δ: 1.17-1.24 [complex 
signal, 3 H, 4’-Hax, 3’(5’)-Hax], 1.43 [complex signal, 2 H, 2’(6’)-Hax], 1.60-1.66 
[complex signal, 3 H, 2’(6’)-Heq, 4’-Heq], 1.75-1.78 [complex signal, 2 H, 3’(5’)-Heq], 
2.13 (tt, J = 12.0 Hz, J’ = 3.5 Hz, 1 H, 1’-H), 2.67 [m, 2 H, 10(11)-H], 2.98 [complex 
signal, 4 H, 6(12)-H, 9(15)-H], 3.18 (s, 2 H, 2-H2 or 4-H2), 3.19 (s, 2 H, 4-H2 or 2-H2), 
6.00 [ddd, J = 6 Hz, J’ = 3 Hz, J’’ = 1.5 Hz, 2 H, 7(13)-H or 8(14)-H], 6.04 [ddd, J = 6 
Hz, J’ = 3 Hz, J’’ = 1 Hz, 2 H, 8(14)-H or 7(13)-H]; 13C-NMR (125.7 MHz, CDCl3) δ: 
25.8 (CH2, C4’), 25.9 [CH2, C3’(5’)], 28.7 [CH2, C2’(6’)], 42.5 (CH, C1’), 45.5 (CH2, 
C2 or C4), 46.7 (CH2, C4 or C2), 62.0 [CH, C6(12) and C9(15)], 62.8 [CH, C10(11)], 
69.1 (C, C1 or C5), 70.8 (C, C5 or C1), 132.8 [CH, C7(13) or 8(14)], 134.1 [CH, 
C8(14) or C7(13)], 174.4 (C, CO); MS (EI), (rt = 25.4 min), m/z (%); significant ions: 
308 (20), 307 (M·+, 83), 252 (16), 242 (25), 198 (17), 197 (100), 196 [(C14H14N)+, 39], 
182 (19), 181 (15), 180 (41), 179 (16), 168 (24), 167 (25), 166 (15), 165 (38), 156 (21), 
153 (23), 152 (27), 132 (64), 131 (100), 130 (64), 128 (17), 118 (19), 117 (19), 115 (23), 
91 (18), 83 [(C6H11)+, 85], 77 (15), 55 (72); HRMS-ESI+ m/z [M+H]+ calcd for 
[C21H25NO+H]+: 308.2009, found: 308.2003. 
6.1.8. (3-Azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadecane-3-yl)(cyclohexyl) 
methanone, (12). 
From amide 11 (118 mg, 0.40 mmol) and Pd/C (13 mg) and following the general 
procedure D (5 h), amide 12 (94 mg, 78% yield) was obtained as a white solid. The 
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analytical sample was obtained by crystallization from DCM/diethyl ether, mp 134 ̶ 135 
ºC; IR (ATR) ν: 2932, 2851, 1621, 1463, 1426, 1357, 1286, 1202, 1120, 1104, 1036, 
1013, 969, 925, 886, 860, 825, 768, 732, 702, 657, 627 cm-1; 1H-NMR (500 MHz, 
CDCl3) δ: 1.25 [complex signal, 3 H, 4’-Hax, 3’(5’)-Hax], 1.48-1.57 [complex signal, 10 
H, 7(13)-H2, 8(14)-H2, 17(21)-Hax], 1.68 (m, 1 H, 4’-Heq), 1.75-1.82 [complex signal, 4 
H, 2’(6’)-Heq, 3’(5’)-Heq], 2.08 (broad signal, 4 H, 6(12)-H, 9(15)-H], 2.36 (tt, J = 12 
Hz, J’ = 3.5 Hz, 1 H, 1’-H), 2.41 [m, 2 H, 10(11)-H], 3.29 [s, 4 H, 2(4)-H2]; 13C-NMR 
(125.7 MHz, CDCl3) δ: 21.5 [CH2, C7(13) or C8(14)], 21.8 [CH2, C8(14) or C7(13)], 
25.8 (CH2, C4’), 25.9 [CH2, C3’(5’)], 29.0 [CH2, C2’(6’)], 40.7 (CH2, C2 or C4), 42.0 
(CH2, C4 or C2), 42.9 (CH, C1’), 49.6 [CH, C10(11)], 55.0 [CH, C6(12) or C9(15)], 
55.1 [CH, C9(15) or C6(12)], 57.5 (C, C1 or C5], 59.3 (C, C5 or C1], 175.1 (C, CO); 
MS (EI), (rt = 26.7 min), m/z (%); significant ions: 312 (23), 311 (M·+, 100), 270 (14), 
257 (19), 256 (99), 243 (12), 228 [(C15H18NO)+ 13], 202 (12), 201 (30), 184 (29), 129 
(15), 128 (15), 91 (16), 83 [(C6H11)+, 24], 55 (25). Anal. Calcd for C21H29NO: C 80.98, 
H 9.39, N 4.50. Found: 80.76, H 9.61, N 4.33. 
6.1.9. (3-Azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadeca-7,13-diene-3-yl)(piperidin-
1-yl)methanone, (13). 
From amine 10 [38] (400 mg, 2.03 mmol), 1-piperidinecarbonyl chloride (0.26 mL, 
2.13 mmol) and triethylamine (0.56 mL, 4.06 mmol) in DCM and following the general 
procedure B amide 13 (443 mg, 71% yield) was obtained as a clear oil. Several attempts 
to crystallize this product met with failure. The product was used in the next step 
without further purification or characterization; MS (EI), (rt = 24.2 min), m/z (%); 
significant ions: 308 (M·+, 46), 196 [(C14H14N)+, 17], 165 (14), 130 (15), 112 
[(C6H10NO)+, 100], 84 [(C5H10N)+, 17], 69 (41). 
6.1.10. (3-Azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadeca-3-yl)(piperidin-1-yl) 
methanone, (14). 
From urea 13 (235 mg, 0.76 mmol) and Pd/C (24 mg) and following the general 
procedure D (3 h), urea 14 (171 mg, 72% yield) was obtained as a white solid, mp 124  ̶
126 ºC; IR (ATR) ν: 3457, 3291, 2936, 2867, 2839, 1615, 1538, 1461, 1415, 1370, 
1332, 1304, 1252, 1226, 1202, 1159, 1124, 1110, 1027, 991, 915, 882, 851, 767, 722, 
632 cm-1; 1H-NMR (500 MHz, CDCl3) δ: 1.47-1.58 [complex signal, 14 H, 7(8,13,14)-
H2, 3’(5’)-H2, 4’-H2], 2.05 [m, 4 H, 6(9,12,15)-H], 2.38 [m, 2 H, 10(11)-H], 3.19 [m, 8 
H, 2(4)-H2, 2’(6’)-H2]; 13C-NMR (125.7 MHz, CDCl3) δ: 21.7 [CH2, C7(8, 13, 14)], 
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24.8 (CH2, C4’), 25.9 [CH2, C3’(5’)], 43.3 [CH2, C2(4)], 47.8 [CH2, C16(20)], 49.6 
[CH, C10(11)], 54.8 [CH, C6(9, 12, 15)], 58.8 [C, C1(5)], 163.3 (C, CO); MS (EI), (rt = 
25.1 min), m/z (%); significant ions: 312 (M·+, 100), 201 (15), 200 [(C14H18N)+, 82], 
184 (33), 129 (36), 112 [(C6H10NO)+, 54], 91 (16), 84 [(C5H10N)+, 59], 69 (28). Anal. 
Calcd for C20H28N2O: C 76.88, H 9.03, N 8.97. Found: 76.60, H 9.21, N 8.74. 
6.1.11. (4-Amino-3,5-dichlorophenyl)(3-
azahexacyclo[7.6.0.01,5.05,12.06,10.011,15]pentadeca-7,13-dien-3-yl)methanone, (15).  
From amine 10 [38] (400 mg, 2.03 mmol), 4-amino-3,5-dichlorobenzoic acid (380 mg, 
1.85 mmol), 1-hydroxybenzotriazole (HOBt) (375 mg, 2.78 mmol), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) (430 mg, 2.78 mmol) and triethylamine 
(0.560 mL, 4.07 mmol) in EtOAc (30 mL) and DMF (2 mL) and following the general 
procedure C, a yellow solid (677 mg) was obtained. Column chromatography (Al2O3, 
DCM/methanol) furnished 15 (332 mg, 47% yield) as a white solid, mp 236 ̶ 238 ºC; IR 
(ATR) ν: 3449, 3306, 3250, 3204, 2954, 2867, 2150, 1597, 1538, 1501, 1456, 1410, 
1384, 1342, 1316, 1295, 1244, 1225, 1192, 1054, 1002, 943, 896, 875, 791, 745, 733, 
686, 667, 643 cm-1; 1H-NMR (500 MHz, CDCl3) δ: 2.61 [m, 2 H, 10(11)-H], 2.85 
[broad s, 2 H, 6(12)-H or 9(15)-H], 2.94 [broad s, 2 H, 9(15)-H or 6(12)-H], 3.13 (broad 
s, 2 H, 2-H or 4-H), 3.33 (broad s, 2 H, 4-H or 2-H), 5.91 [m, 2 H, 7(13)-H or 8(14)-H], 
6.03 [m, 2 H, 8(14)-H or 7(13)-H], 7.19 (s, 2 H, Ar-H); 13C-NMR (125.7 MHz, CDCl3) 
δ: 45.5 (CH2, C2 or C4), 49.9 (CH2, C4 or C2), 61.8 [CH, C6(12), C9(15)], 62.7 [CH, 
C10(11)], 68.8 (C, C1 or C5), 71.0 (C, C5 or C1), 118.7 (C, Ar-Cmeta), 126.7 (C, Cipso), 
127.1 (CH, Ar-Cortho), 132.9 [CH, C7(13) or 8(14)], 133.9 [CH, C8(14) or C7(13)], 
141.3 (C, Ar-Cpara), 166.8 (C, CO); GC/MS (EI), (rt = 30.7 min), m/z (%); significant 
ions: 388 [(C21H1837Cl2N2O)·+, 2], 386 [(C21H1837Cl35ClN2O)·+, 12], 384 
[(C21H1835Cl2N2O)·+, 18], 192 [(C7H437Cl2NO)+, 10],, 190 [(C7H437Cl35ClNO)+, 63], 188 
[(C7H435Cl2NO)+, 100], 180 (12), 160 (12), 124 (16); HRMS-ESI+ m/z [M+H]+ calcd 
for [C21H18Cl2N2O+H]+: 385.0869, found: 385.0875. 
6.1.12. (4-Amino-3,5-dichlorophenyl) (3-azahexacyclo[7.6.0.01,5.05,12.06,10.011,15] 
pentadecan-3-yl)methanone, (16). 
From amide 15 (200 mg, 0.78 mmol) and Pd/C (24 mg) and following the general 
procedure D (5 h) a yellow solid (207 mg) was obtained. Column chromatography 
(Al2O3, DCM/methanol) gave the desired amide 16 (180 mg, 89% yield) as a white 
solid, mp 243 ̶ 244 ºC; IR (ATR) ν: 3455, 3283, 3238, 3186, 2931, 2865, 1631, 1597, 
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1545, 1498, 1456, 1425, 1332, 1307, 1269, 1232, 1216, 1118, 1070, 1035, 944, 895, 
789, 768, 745, 693, 647, 629 cm-1; 1H-NMR (500 MHz, CDCl3) δ: 1.43-1.60 [complex 
signal, 8 H, 7(13)-H2, 8(14)-H2], 2.04 [broad s, 2 H, 6(12)-H or 9(15)-H], 2.12 [broad s, 
2 H, 9(15)-H or 6(12)-H], 2.41 [m, 2 H, 10(11)-H], 3.29 (s, 2 H, 2-H2 or 4-H2), 3.53 (s, 
2 H, 4-H2 or 2-H2), 7.40 (s, 2 H, Ar-H); 13C-NMR (125.7 MHz, CDCl3) δ: 21.5 [CH2, 
C7(13) or C8(14)], 21.8 [CH2, C8(14) or C7(13)], 40.8 (CH2, C2 or C4), 45.5 (CH2, C4 
or C2), 49.6 [CH, C10(11)], 54.8 [broad CH, C6(12) and C9(15)], 57.9 (C, C1 or C5), 
59.6 (C, C5 or C1), 118.8 (C, Ar-Cmeta), 126.9 (C, Cipso), 127.2 (CH, Ar-Cortho), 141.4 
(C, Ar-Cpara), 167.0 (C, CO); MS (EI), (rt = 32.3 min), m/z (%); significant ions: 392 
[(C21H2237Cl2N2O)·+, 8], 390 [(C21H2237Cl35ClN2O)·+, 42], 388 [(C21H2235Cl2N2O)·+, 63], 
200 (18), 192 [(C7H437Cl2NO)+, 11], 190 [(C7H437Cl35ClNO)+, 64], 188 
[(C7H435Cl2NO)+, 100], 184 (33), 169 (13), 160 (12), 124 (13). Anal. Calcd for 
C21H22Cl2N2O·0.50H2O: C 63.32, H 5.82, Cl 17.80, N 7.03. Found: C 63.23, H 5.71, Cl 
17.82, N 6.77. 
6.1.13. (Cyclohexyl)(octahydro-2H-isoindol-2-yl)methanone, (17). 
From octahydro-1H-isoindole hydrochloride (300 mg, 2.40 mmol), 
cyclohexanecarboxylic acid (279 mg, 2.18 mmol), HOBt (442 mg, 3.27 mmol), EDC 
(506 mg, 3.27 mmol) and triethylamine (0.7 mL, 4.80 mmol) in EtOAc (10 mL) and 
following the general procedure C, 17 (458 mg, 89% yield) was obtained as a white 
solid. The analytical sample was obtained by crystallization from hot EtOAc (82 mg), 
mp  67 – 68 ºC; IR (ATR) ν: 734, 890, 973, 1073, 1113, 1136, 1173, 1184, 1307, 1341, 
1358, 1443, 1481, 1622, 2851, 2873, 2917 cm-1; 1H-NMR (400 MHz, CDCl3) δ: 1.16-
1.30 (complex signal, 3 H, 3-Hax, 4-Hax and 5-Hax), 1.31-1.63 (complex signal, 10 H, 2-
Hax, 6-Hax, 4’-H2, 7’-H2, 5’-H2, 6’-H2), 1.64-1.84 (complex signal, 5 H, 2-Heq, 6-Heq, 3-
Heq, 4-Heq and 5-Heq), 2.16 (m, 1 H, 3a’-H or 7a’-H), 2.24 (m, 1 H, 7a’-H or 3a’-H), 
2.30 [tt, J = 11.6 Hz, J’ = 3.6 Hz, 1 H, 1-H], 3.31 (dd, J = 10.0 Hz, J’ = 6.0 Hz, 1 H, 1’-
Ha or 3´-Ha), 3.36 (dd, J = 12.0 Hz, J’ = 6.6 Hz, 1 H, 3’-Ha or 1´-Ha), 3.40 (dd, J = 12.0 
Hz, J’ = 7.8 Hz, 1 H, 3’-Hb or 1´-Hb), 3.45 (dd, J = 10.0 Hz, J’ = 7.0 Hz, 1 H, 1’-Hb or 
3´-Hb); 13C-NMR (100.5 MHz, CDCl3) δ: 22.5 (CH2, C5’ or C6’), 22.8 (CH2, C6’ or 
C5’), 25.73 (CH2), 25.78 (CH2), 25.80 (CH2), 25.84 (CH2) and 25.91 (CH2) [C4’, C7’, 
C3, C4 and C5], 28.8 (CH2, C2 or C6), 29.0 (CH2, C6 or C2), 35.8 (CH, C3a’ or C7a’), 
37.6 (CH, C7a’ or C3a’), 42.7 (CH, C1), 49.3 (CH2, C1’ or C3’), 50.4 (CH2, C3’ or 
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C1’), 175.4 (C, CO). Anal. Calcd for C15H25NO: C 76.55, H 10.71, N 5.95. Found: 
76.56, H 10.67, N 5.96. 
6.1.14 (4-Azatricyclo[5.2.1.02,6]dec-8-en-4-yl)(cyclohexyl)methanone, (18). 
From 4-azatricyclo[5.2.1.02,6]dec-8-ene hydrochloride [58] (240 mg, 1.40 mmol), 
cyclohexanecarboxylic acid (163 mg, 1.27 mmol), HOBt (258 mg, 1.91 mmol), EDC 
(296 mg, 1.91 mmol) and triethylamine (0.8 mL, 5.59 mmol) in EtOAc (8 mL) and 
following the general procedure C, amide 18 (304 mg, 97% yield) was obtained as a 
yellowish solid. Column chromatography (hexane/EtOAc) gave 18 as a white solid (209 
mg), mp 77 ̶ 78 ºC; IR (ATR) ν: 702, 731, 761, 793, 897, 987, 1216, 1256, 1332, 1347, 
1428, 1621, 2850, 2920 cm-1; 1H-NMR (400 MHz, CDCl3) δ: 1.12-1.29 (complex 
signal, 3 H, 3-Hax, 4-Hax and 5-Hax), 1.36-1.51 (complex signal, 3 H, 2-Hax, 6-Hax and 
10’-Ha], 1.54 (dt, J = 8.4 Hz, J’ = 1.6 Hz, 1 H, 10’-Hb), 1.60-1.70 [complex signal, 3 H, 
2-Heq, 6-Heq and 4-Heq), 1.71-1.84 (complex signal, 2 H, 3-Heq and 5-Heq), 2.16 (tt, J = 
11.6 Hz, J’ = 3.6 Hz, 1 H, 1-H), 2.82-3.00 (complex signal, 4 H, 1’-H, 7’-H, 2’-H and 
6’-H), 3.10 (dd, J = 10.8 Hz, J’ = 3.6 Hz, 1 H, 3’-Ha or 5’- Ha), 3.21 (dd, J = 13.5 Hz, J’ 
= 3.6 Hz, 1 H, 5’-Ha or 3’- Ha), 3.29 (dd, J = 13.5 Hz, J’ = 9.2 Hz, 1 H, 5’-Hb or 3’- Hb), 
3.43 (dd, J = 10.8 Hz, J’ = 9.2 Hz, 1 H, 3’-Hb or 5’- Hb), 6.14 (dd, J = 6.0 Hz, J’ = 3.2 
Hz, 1 H, 8’-H or 9’-H), 6.19 (dd, J = 6.0 Hz, J’ = 3.2 Hz, 1 H, 9’-H or 8’-H); 13C-NMR 
(100.5 MHz, CDCl3) δ: 25.8 [CH2, C3(5)], 25.9 (CH2, C4), 28.69 (CH2, C2 or C6), 
28.71 (CH2, C6 or C2), 42.7 (CH, C1), 43.8 (CH, C2’ or C6’), 45.9 (CH, C6’ or C2’), 
46.66 (CH, C1’ or C7’), 46.70 (CH, C7’ or C1’), 48.0 (CH2, C3’ or C5’), 48.8 (CH2, C5’ 
or C3’), 51.9 (CH2, C10’), 134.7 (CH, C8’ or C9’), 136.1 (CH, C9’ or C8’), 173.9 (C, 
CO). Anal. Calcd for C16H23NO: C 78.32,  H 9.45, N 5.71. Found: 78.03, H 9.41, N 
5.58. 
6.1.15.(4-Azatricyclo[5.2.1.02,6]dec-4-yl)(cyclohexyl)methanone, (19). 
From amide 18 (177 mg) and Pd/C (36 mg) and following the general procedure D (18 
h), amide 19 (156 mg, 88% yield) was obtained as a white solid, mp  83-84 ºC; IR 
(ATR) ν: 611, 625, 642, 886, 1002, 1133, 1170, 1187, 1204, 1218, 1290, 1327, 1344, 
1357, 1425, 1446, 1623, 2871, 2936, 2945 cm-1; 1H-NMR (400 MHz, CDCl3) δ: 1.20  ̶
1.94 (complex signal, 16 H, 3-H2, 4-H2, 5-H2, 2-H2, 6-H2, 8’-H2, 9’-H2 and 10’-H2), 
2.18-2.27 (complex signal, 2 H, 1’-H and 7’-H), 2.37 (tt, J = 11.6 Hz, J’ = 3.2 Hz, 1 H, 
1-H), 2.52 (m, 1 H, 2’-H or 6’-H), 2.60 (m, 1 H, 6’-H or 2’-H), 3.03 (dd, J = 13.2 Hz, J’ 
= 8.4 Hz, 1 H, 3’-Ha or 5’- Ha), 3.26 (dd, J = 11.6 Hz, J’ = 7.6 Hz, 1 H, 5’-Ha or 3’- Ha), 
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3.57 (dd, J = 11.6 Hz, J’ = 1.6 Hz, 1 H, 5’-Hb or 3’- Hb), 3.84 (dd, J = 13.2 Hz, J’ = 1.6 
Hz, 1 H, 3’-Hb or 5’- Hb); 13C-NMR (100.5 MHz, CDCl3) δ: 22.1 (CH2, C8’ or C9’), 
22.8 (CH2, C9’ or C8’), 25.79 (CH2), 25.86 (CH2) and 25.88 (CH2) (C3, C4 and C5), 
28.87 (CH2, C2 or C6), 28.89 (CH2, C6 or C2), 41.2 (CH, C1’ or C7’), 41.4 (CH, C7’ or 
C1’), 42.0 (CH2, C2’ or C6’), 42.1 (CH2, C10’), 42.9 (CH, C1), 44.0 (CH2, C6’ or C2’), 
45.7 (CH2, C3’ or C5’), 46.9 (CH2, C5’ or C3’), 174.4 (C, CO). Anal. Calcd for 
C16H25NO: 77.68, H 10.19, N 5.66. Found: C 77.55, H 10.05, N 5.54. 
6.1.16. (4-Azatricyclo[5.2.2.02,6]undec-8-en-4-yl)(cyclohexyl)methanone, (20). 
From 4-azatricyclo[5.2.2.02,6]undec-8-ene hydrochloride [59] (300 mg, 1.62 mmol), 
cyclohexanecarboxylic acid (188 mg, 1.47 mmol), HOBt (300 mg, 2.21 mmol), EDC 
(342 mg, 2.21 mmol) and triethylamine (0.9 mL, 6.47 mmol) in EtOAc (10 mL) and 
following the general procedure C, amide 20 (323 mg, 85% yield) was obtained as a 
yellowish solid. Column chromatography (hexane/EtOAc) gave 20 as a white solid (205 
mg), mp  86 ̶ 87 ºC; IR (ATR) ν: 703, 715, 849, 887, 986, 1044, 1132, 1165, 1216, 1239, 
1307, 1347, 1357, 1375, 1431, 1625, 2850, 2921, 3037 cm-1; 1H-NMR (400 MHz, 
CDCl3) δ: 1.15-1.34 (complex signal, 5 H, 10’-Ha, 11’-Ha, 3-Hax, 4-Hax and 5-Hax), 
1.37-1.54 (complex signal, 4 H, 2-Hax, 6-Hax, 10’-Hb, 11’-Hb), 1.58-1.86 (complex 
signal, 5 H,  2-Heq, 6-Heq, 3-Heq, 4-Heq and 5-Heq), 2.23 (tt, J = 11.6 Hz, J’ = 3.6 Hz, 1 
H, 1-H), 2.42 (m, 1 H, 2’-H or 6’-H), 2.51-2.61 (complex signal, 3 H, 1’-H, 7’-H, 6’-H 
or 2’-H), 3.09 (d, J = 12.8 Hz, 1 H, 3’-Ha or 5’-Ha), 3.11 (d, J = 12.4 Hz, 1 H, 5’-Ha and 
3’-Ha), 3.62 (dd, J = 12.4 Hz, J’ = 9.2 Hz, 1 H, 5’-Hb or 3’-Hb), 3.65 (dd, J = 12.8 Hz, J’ 
= 9.6 Hz, 1 H, 3’-Hb and 5’-Hb), 6.15-6.26 (complex signal, 2 H, 8’-H and 9’-H); 13C-
NMR (100.5 MHz, CDCl3) δ: 24.2 (CH2, C10’ or C11’), 24.3 (CH2, C11’ or C10’), 
25.81 (CH2), 25.84 (CH2) and 25.9 (CH2) [C3, C4 and C5], 28.7 (CH2, C2 or C6), 28.8 
(CH2, C6 or C2), 34.1 (CH, C1’ and C7’), 41.9 (CH, C2’ or C6’), 42.6 (CH, C1), 44.0 
(CH, C6’ or C2’), 50.8 (CH2, C3’ or C5’), 51.6 (CH2, C5’ or C3’), 132.9 (CH, C8’ or 
C9’), 134.3 (CH, C9’ or C8’), 173.9 (C, CO). Anal. Calcd for C17H25NO: C 78.72, 9.71, 
N 5.40. Found: C 78.82, H 9.71, N 5.30. 
6.1.17. (4-Azatricyclo[5.2.2.02,6]undec-4-yl)(cyclohexyl)methanone, (21). 
From amide 20 (165 mg) and Pd/C (33 mg) and following the general procedure D (18 
h) amide 21 (151 mg, 91% yield) was obtained as a white solid, mp  78 ̶ 79 ºC; IR 
(ATR) ν: 622, 725, 868, 976, 1138, 1173, 1204, 1346, 1429, 1443, 1622, 2861, 2901, 
2923 cm-1; 1H-NMR (400 MHz, CDCl3) δ: 1.18-1.42 (complex signal, 5 H, 3-Hax, 4-
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Hax, 5-Hax, 8’-Ha and 9’-Ha), 1.44-1.90 (complex signal, 15 H, 3-Heq, 4-Heq, 5-Heq, 2-H2, 
6-H2, 1’-H, 7’-H, 8’-Hb, 9’-Hb, 10’-H2 and 11’-H2), 2.33 (m, 1 H, 2’-H or 6’-H), 2.37 
(tt, J = 11.2 Hz, J’ = 3.4 Hz, 1 H, 1-H), 2.43 (m, 1 H, 6’-H and 2’-H), 3.44-3.65 
(complex signal, 4 H, 3’-H2 and 5’-H2); 13C-NMR (100.5 MHz, CDCl3) δ: 19.8 (CH2, 
C9’ or C8’), 20.1 (CH2, C8’ or C9’), 25.7 (CH, C1’ and C7’), 25.81 (CH2), 25.86 (CH2) 
and 25.91 (CH2) (C3, C4 and C5), 27.8 (CH2, C11’ or C10’), 28.0 (CH2, C10’ or C11’), 
28.86 (CH2, C2 or C6), 28.92 (CH2, C6 or C2), 37.8 (CH2, C2’ or C6’), 40.0 (CH2, C6’ 
or C2’), 42.8 (CH, C1), 49.1 (CH2, C3’ or C5’), 49.9 (CH2, C5’ or C3’), 174.3 (C, CO). 
Anal. Calcd for C17H27NO: C 78.11, H 10.41, N 5.36. Found: C 78.14, H 10.35, N 5.14. 
6.1.18. (4-Azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl)(cyclohexyl)methanone, (22).  
From 4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-ene hydrochloride [40] (2.06 g, 10.6 
mmol), cyclohexanecarboxylic acid (1.24 g, 9.67 mmol), HOBt (1.96 g, 14.5 mmol), 
EDC (2.25 g, 14.5 mmol) and triethylamine (5.9 mL, 42.5 mmol) in EtOAc (150 mL) 
and following the general procedure C, amide 22 (2.43 g, 94% yield) was obtained as a 
yellowish solid. The analytical sample was obtained by crystallization from hot EtOAc 
(2.04 g), mp  96 ̶ 97 ºC; IR (ATR) ν: 560, 570, 587, 696, 718, 741, 767, 812, 829, 847, 
894, 915, 942, 963, 991, 1036, 1089, 1134, 1167, 1209, 1217, 1242, 1272, 1299, 1361, 
1380, 1432, 1624, 2849, 2925, 3002, 3040 cm-1; 1H-NMR (400 MHz, CDCl3) δ: 0.12-
0.16 (complex signal, 2 H, 9’-H2), 0.86-0.96 (complex signal, 2 H, 8’-H and 10’-H), 
1.14-1.29 (complex signal, 3 H, 3-Hax, 4-Hax and 5-Hax), 1.36-1.53 (complex signal, 2 
H, 2-Hax and 6-Hax), 1.60-1.70 (complex signal, 3 H, 2-Heq, 4-Heq and 6-Heq), 1.72-1.80 
(complex signal, 2 H, 3-Heq and 5-Heq), 2.21 (tt, J = 11.6 Hz, J’ = 3.4 Hz, 1 H, 1-H), 
2.55 (dm, J = 12.8 Hz, 1 H, 2’-H or 6’-H), 2.67 (dm, J = 12.8 Hz, 1 H, 6’-H or 2’-H), 
2.81-2.87 (complex signal, 2 H, 1’-H and 7’-H), 3.12 (dd, J = 11.0 Hz, J’ = 5.0 Hz, 1 H, 
3’-Ha or 5’-Ha), 3.15 (dd, J = 13.2 Hz, J’ = 5.6 Hz, 1 H, 5’-Ha or 3’-Ha), 3.55 (t, J = 10.0 
Hz, 1 H, 5’-Hb or 3’-Hb), 3.58 (t, J = 8.8 Hz, 1 H, 3’-Hb or 5’-Hb), 5.73 (ddd, J = 14.4 
Hz, J’ = 8.4 Hz, J’’ = 2.0 Hz, 1 H, 11’-H or 12’-H], 5.77 (ddd, J = 14.4 Hz, J’ = 8.4 Hz, 
J’’ = 2.0 Hz, 1 H, 12’-H or 11’-H]; 13C-NMR (100.5 MHz, CDCl3) δ: 4.1 (CH2, C9’), 
10.0 (CH, C8’ or C10’), 10.2 (CH, C10’ or C8’), 25.80 (CH2), 25.83 (CH2) and 25.9 
(CH2) [C3, C4 and C5], 28.7 (CH2, C2 or C6), 28.8 (CH2, C6 or C2), 35.6 (CH, C1’ or 
C7’), 35.7 (CH, 7’ or C1’), 42.6, (CH, C1), 42.7 (CH, C2’ or C6’), 44.8 (CH, C6’ or 
C2’), 49.6 (CH2, C3’ or C5’), 50.6 (CH2, C5’ or C3’), 128.1 (CH, C11’ or C12’), 129.6 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
31 of 52 
 
(CH, C12’ or C11’), 174.1 (C, CO). Anal. Calcd for C18H25NO: C 79.66, H 9.29, N 
5.16. Found: C 79.64, H 9.24, N 5.21. 
6.1.19. (4-Azatetracyclo[5.3.2.02,6.08,10]dodec-4-yl)(cyclohexyl)methanone, (23). 
From 22 (500 mg) and Pd/C (100 mg) and following the general procedure D (72 h) 
amide 23 (426 mg, 83% yield) was obtained as a white solid, mp  74 ̶ 75 ºC; IR (ATR) 
ν: 651, 679, 707, 729, 748, 789, 805, 826, 839, 865, 885, 950, 961, 988, 1016, 1030, 
1082, 1113, 1133, 1171, 1205, 1213, 1234, 1264, 1295, 1325, 1346, 1358, 1427, 1471, 
1486, 1623, 2846, 2897, 2928, 3009, cm-1; 1H-NMR (400 MHz, CDCl3) δ: 0.45 (dt, J = 
6.0 Hz, J’ = 8.0 Hz, 1 H, 9’-Ha), 0.78 (m, J = 6.0 Hz, J’ = 3.6 Hz, 1 H, 9’-Hb), 0.90-0.96 
(complex signal, 2 H, 8’-H and 10’-H), 1.00-1.14 (complex signal, 2 H, 11’-Hax and 
12’-Hax), 1.17-1.34 [complex signal, 5 H, 11’-Heq, 12’-Heq, 3-Hax, 4-Hax and 5-Hax], 
1.42-1.61 (complex signal, 2 H, 2-Hax and 6-Hax), 1.67 (m, 1 H, 4’-Heq), 1.69-1.83 
(complex signal, 4 H, 3-Heq, 4-Heq, 5-Heq, 6-Heq), 1.84-1.91 (complex signal, 2 H, 1’-H 
and 7’-H), 2.38 [tt, J = 11.6 Hz, J’ = 3.6 Hz, 1 H, 1-H], 2.50 (dm, J = 12.8 Hz, 1 H, 2’-
H or 6’-H), 2.55 (dm, J = 12.8 Hz, 1 H, 6’-H or 2’-H), 3.32 (dd, J = 12.8 Hz, J’ = 8.8 
Hz, 1 H, 3’-Ha or 5’-Ha), 3.52 (m, 2 H, 5’-H2 or 3’-H2), 3.76 (dd, J = 12.8 Hz, J’ = 3.0 
Hz, 1 H, 3’-Hb or 5’-Hb); 13C-NMR (100.5 MHz, CDCl3) δ: 4.7 (CH2, C9’), 14.9 (CH, 
C8’ or C10’), 15.1 (CH, C10’ or C8’), 17.3 (CH2, C11’ or C12’), 17.9 (CH2, C12’ or 
C11’), 25.8 (CH2, C4), 25.9 [CH2, C3(5)], 28.87 (CH2, C2 or C6), 28.92 (CH2, C6 or 
C2), 29.0 (CH, C1’ or C7’), 29.4 (CH, C7’ or C1’), 38.4 (CH, C2’ or C6’), 40.5, (CH, 
C6’ or C2’), 42.7 (CH, C1), 48.1 (CH, C3’ or C5’), 49.3 (CH2, C5’ or C3’), 174.4 (C, 
CO). Anal. Calcd for C18H27NO: C 79.07,  H 9.95, N 5.12. Found: 79.15, H 9.88, N 
5.29. 
6.1.20. (4-Azatetracyclo[5.4.2.02,6.08,11]trideca-9,12-dien-4-yl)(cyclohexyl) methanone, 
(24). 
From 4-azatetracyclo[5.4.2.02,6.08,11]trideca-9,12-diene hydrochloride [40] (139 mg, 
0.66 mmol), cyclohexanecarboxylic acid (77 mg, 0.60 mmol), HOBt (122 mg, 0.90 
mmol), EDC (139 mg, 0.90 mmol) and triethylamine (0.4 mL, 2.64 mmol) in EtOAc (6 
mL) and following the general procedure C, amide 24 (151 mg, 80% yield) was 
obtained as a yellowish solid. The analytical sample was obtained by crystallization 
from hot EtOAc (97 mg), mp  120 ̶ 121 ºC; IR (ATR) ν: 730, 760 788, 808, 967, 994, 
1173, 1187, 1214, 1235, 1294, 1361, 1442, 1463, 1617, 2860, 2901, 2922 cm-1; 1H-
NMR (400 MHz, CDCl3) δ: 1.15-1.30 [complex signal, 3 H, 3-Hax, 4-Hax and 5-Hax], 
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1.38-1.54 [complex signal, 2 H, 2-Hax and 6-Hax], 1.60-1.72 (complex signal, 3 H, 2-
Heq, 4-Heq and 6-Heq), 1.73-1.82 (complex signal, 2 H, 3-Heq and 5-Heq), 2.24 [tt, J = 
11.6 Hz, J’ = 3.6 Hz, 1 H, 1-H],  2.37 (tdd, J = 9.6 Hz, J’ = 5.8 Hz, J’’ = 2.8 Hz, 1 H, 2’-
H or 6’-H), 2.50 (tdd, J = 8.8 Hz, J’ = 5.6 Hz, J’’ = 2.8 Hz, 1 H, 6’-H or 2’-H), 2.60-
2.66 (complex signal, 2 H, 1’-H and 7’-H), 2.67-2.70 (complex signal, 2 H, 8’-H and 
11’-H), 3.17-3.24 (complex signal, 2 H, 3’-Ha and 5’-Ha), 3.63-3.73 (complex signal, 2 
H, 3’-Hb and 5’-Hb), 5.84-5.87 (complex signal, 2 H, 9’-H and 10’-H), 5.89-5.99 
(complex signal, 2 H, 12’-H and 13’-H); 13C-NMR (100.5 MHz, CDCl3) δ: 25.81 
(CH2), 25.84 (CH2) and 25.9 (CH2) (C3, C4 and C5), 28.7 (CH2, C2 or C6), 28.8 (CH2, 
C6 or C2), 39.36 (CH, C1’ or C7’), 39.37 (CH, C7’ or C1’), 41.1 (CH, C2’ or C6’), 42.6 
(CH, C1), 43.2 (CH, C6’ or C2’), 44.9 (CH, C8’ or C11’), 45.1 (CH, C11’ or C8’), 50.7 
(CH2, C3’ or C5’), 51.5 (CH2, C5’ or C3’), 129.0 (CH, C12’ or C13’), 130.3 (CH, C13’ 
or C12’), 137.7 (CH, C9’ or C10’), 138.0 (CH, C10’ or C9’), 174.0 (C, CO). Anal. 
Calcd for C19H25NO: C 80.52, H 8.89, N 4.94. Found: 80.31, H 8.81, N  4.97. 
6.1.21. (4-Azatetracyclo[5.4.2.02,6.08,11]tridec-4-yl)(cyclohexyl)methanone, (25). 
From 4-azatetracyclo[5.4.2.02,6.08,11]tridecane hydrochloride [40] (235 mg, 1.10 mmol), 
cyclohexanecarboxylic acid (128 mg, 1.0 mmol), HOBt (203 mg, 1.50 mmol), EDC 
(232 mg, 1.50 mmol) and triethylamine (0.6 mL, 4.40 mmol) in EtOAc (10 mL) and 
following the general procedure C, amide 25 (253 mg, 80% yield) was obtained as a 
yellowish solid. The analytical sample was obtained by crystallization from hot EtOAc 
(110 mg), mp  115 ̶ 116 ºC; IR (ATR) ν: 658, 731, 887, 988, 1133, 1172, 1204, 1236, 
1357, 1434, 1440, 1621, 2908, 2925 cm-1; 1H-NMR (400 MHz, CDCl3) δ: 1.18-1.34 
(complex signal, 3 H, 3-Hax, 4-Hax and 5-Hax), 1.42-1.62 (complex signal, 6 H, 1’-H, 7’-
H, 2-Hax, 6-Hax, 12’-Ha and 13’-Ha), 1.64-1.92 (complex signal, 7 H, 2-Heq, 6-Heq, 3-
Heq, 4-Heq, 5-Heq, 12’-Hb and 13’-Hb), 2.02-2.20 (complex signal, 5 H, 2’-H or 6’-H, 9’-
Ha, 9’-Hb, 10’-Ha and 10’-Hb), 2.27 (m, 1 H, 6’-H or 2’-H), 2.34-2.44 (complex signal, 
3 H, 1-H, 8’-H and 11’-H), 3.48-3.70 (complex signal, 4 H, 3’-H2 and 5’-H2); 13C-NMR 
(100.5 MHz, CDCl3) δ: 15.0 (CH2, C12’ or C13’), 15.3 (CH2, C13’ or C12’), 20.8 [CH2, 
C9’(10’)], 25.82 (CH2), 25.88 (CH2) and 25.92 (CH2) (C3, C4 and C5), 28.88 (CH2, C2 
or C6), 28.95 (CH2, C6 or C2), 31.2 (CH, C1’ or C7’), 31.5 (CH, C7’ or C1’), 36.37 
(CH, C8’ or C11’), 36.44 (CH, C11’ or C8’), 37.4 (CH, C2’ or C6’), 39.5 (CH, C6’ or 
C2’), 42.8 (CH, C1), 48.8 (CH2, C3’ or C5’), 49.7 (CH2, C5’ or C3’), 174.4 (C, CO). 
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Anal. Calcd for C19H29NO: C 79.39, H 10.17, N  4.87. Found: C 79.20, H 10.30, N 
4.72. 
6.1.22. (12-Azatricyclo[4.4.3.01,6]trideca-3,8-dien-12-yl)(cyclohexyl)methanone,  (26).  
From 12-azatricyclo[4.4.3.01,6]trideca-3,8-diene hydrochloride [41] (150 mg, 0.71 
mmol), cyclohexanecarboxylic acid (82 mg, 0.64 mmol), HOBt (131 mg, 0.97 mmol), 
EDC (150 mg, 0.97 mmol) and triethylamine (0.4 mL, 2.82 mmol) in EtOAc (6 mL) 
and following general procedure C, amide 26 (185 mg, 92% yield) was obtained as a 
yellowish solid. The analytical sample was obtained by crystallization from hot EtOAc 
(106 mg), mp  116 ̶ 117 ºC; IR (ATR) ν: 605, 676, 739, 813, 865, 1004, 1187, 1207, 
1224, 1332, 1347, 1427, 1629, 2858, 2918 cm-1; 1H-NMR (400 MHz, CDCl3) δ: 1.16-
1.31 (complex signal, 3 H, 3(5)-Hax and 4-Hax), 1.51 [m, 2 H, 2(6)-Hax], 1.62-1.84 
[complex signal, 5 H, 2(6)-Heq, 3(5)-Heq and 4-Heq], 1.92-2.10 [complex signal, 8 H, 
2’(10’)-H2 and 5’(7’)-H2], 2.29 [tt, J = 11.6 Hz, J’ = 3.6 Hz, 1 H, 1-H], 3.35-3.37 
(complex signal, 4 H, 3’-Ha, 3’-Hb, 5’-Ha and 5’-Hb), 5.48-5.57 [complex signal, 4 H, 
3’(9’)-H and 4’(8’)-H]; 13C-NMR (100.5 MHz, CDCl3) δ: 25.8 (CH2, C4), 25.9 [CH2, 
C3(5)], 28.9 [CH2, C2(6)], 32.1 [CH2, C2’(10’) or C5’(7’)], 32.2 [CH2, C5’(7’) or 
C2’(10’)], 37.3 (C, C1’ or C6’), 39.2 (C, C6’ or C1’), 42.6 (CH, C1), 55.3 (CH2, C11’ or 
C13’), 56.1 (CH2, C13’ or C11’), 123.3 (CH, C3’ and C9’), 123.9 (CH, C4’ and C8’), 
176.3 (C, CO); HRMS-ESI+ m/z [M+H]+ calcd for [C19H27NO+H]+: 286.2165, found: 
286.2176. 
6.1.23. (12-Azatricyclo[4.4.3.01,6]tridec-12-yl)(cyclohexyl)methanone, (27). 
From 26 (362 mg) and Pd/C (72 mg) and following the general procedure D (24 h), 
amide 27 (330 mg, 90% yield) was obtained as a white solid. The analytical sample was 
obtained by crystallization from hot EtOAc (178 mg), mp  160 ̶ 161 ºC; IR (ATR) ν: 
670, 764, 874, 891, 976, 1157, 1290, 1343, 1360, 1435, 1623, 1635, 2850, 2907, 2921 
cm-1; 1H-NMR (400 MHz, CDCl3) δ: 1.18-1.29 [complex signal, 3 H, 3(5)-Hax and 4-
Hax], 1.31-1.62 [complex signal, 18 H, 2`(6)-Hax, 3’(9’)-H2, 4’(8’)-H2, 5’(7’)-H2, 
10’(13’)-H2], 1.64-1.84 [complex signal, 5 H, 2(6)-Heq, 3(5)-Heq and 4-Heq], 2.30 [tt, J = 
11.6 Hz, J’ = 3.6 Hz, 1 H, 1-H], 2.70-3.90 (complex signal, 4 H, 3’-H2 and 5’-H2); 13C-
NMR (100.5 MHz, CDCl3) δ: 21.6 [CH2, C3’(9’) or C4’(8’)], 21.8 [CH2, C4’(8’) or 
C3’(9’)], 25.8 (CH2, C4), 25.9 [CH2, C3(5)], 28.9 [CH2, C2(6)], 39.8 (C, C1’ and C6’), 
41.7 [CH2, C2’(10’) and C5’(7’)], 42.6 (CH, C1), 55.1 (CH2, C11’ or C13’), 55.8 (CH2, 
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C13’ or C11’), 176.0 (C, CO). Anal. Calcd for C19H31NO: C 78.84, H 10.80, N 4.84. 
Found: 78.83, H 10.74, N 4.75. 
6.1.24. (3,4,8,9-Tetramethyl-12-azatricyclo[4.4.3.01,6]trideca-3,8-dien-12-yl) 
(cyclohexyl)methanone, (28). 
From 3,4,8,9-tetramethyl-12-azatricyclo[4.4.3.01,6]trideca-3,8-diene hydrochloride [41] 
(136 mg, 0.51 mmol), cyclohexanecarboxylic acid (62 mg, 0.48 mmol), HOBt (111 mg, 
0.82 mmol), EDC (127 mg, 0.82 mmol) and triethylamine (0.3 mL, 2.38 mmol) in 
EtOAc (6 mL) and following the general procedure C, amide 28 (138 mg, 79% yield) 
was obtained as a yellowish solid. Column chromatography (hexane/EtOAc) gave 28 as 
a white solid (74 mg), mp  162 ̶ 163 ºC; IR (ATR) ν: 748, 785, 848, 973, 1118, 1358, 
1434, 1441, 1603, 1613, 2861, 2931 cm-1; 1H-NMR (400 MHz, CDCl3) δ: 1.40-1.1.54 
[complex signal, 3 H, 3(5)-Hax and 4-Hax], 1.56 (s, 12 H, CH3), 1.62-1.98 [complex 
signal, 15 H, 3(5)-Heq, 4-Heq, 2-H2, 6-H2, 2’(10’)-H2, 5’(7’)-H2], 2.28 (tt, 1 H, J = 11.6 
Hz, J’ = 3.2 Hz, 1 H, 1-H), 3.28-3.34 (complex signal, 4 H, 11’-H2 and 13’-H2); 13C-
NMR (100.5 MHz, CDCl3) δ: 18.68 [CH3, H3C-C3’(9’) or H3C-C4’(8’)], 18.71 [CH3, 
H3C-C4’(8’) or H3C-C3’(9’)], 25.8 (CH2, C4), 25.9 [CH2, C3(5)], 28.9 [CH2, C2(6)], 
38.6 (CH2, C1’ or C6’), 38.7 [CH2, C2’(10’) or C5’(7’)], 38.8 [CH2, C5’(7’) or 
C2’(10’)], 40.4 (CH2, C6’ or C1’), 42.6 (CH, C1), 55.5 (CH2, C11’ or C13’), 56.4 (CH2, 
C13’ or C11’), 121.6 [C, C3’(9’) or C4’(8’)], 122.2 (C, C4’(8’) or C3’(9’)], 176.4 (C, 
CO); HRMS-ESI+ m/z [M+H]+ calcd for [C23H36NO+H]+: 342.2791, found: 342.2793. 
6.1.25. (7,8,9,10-Tetramethyl-3-azapentacyclo[7.2.1.15,8.01,5.07,10]tridec-3-yl) 
(cyclohexyl) methanone, (29). 
From 7,8,9,10-tetramethyl-3-azapentacyclo[7.2.1.15,8.01,5.07,10]tridecane hydrochloride 
[40] (145 mg, 0.54 mmol), cyclohexanecarboxylic acid (67 mg, 0.52 mmol), HOBt (105 
mg, 0.78 mmol), ED  (121 mg, 0.78 mmol) and triethylamine (0.3 mL, 2.29 mmol) in 
EtOAc (6 mL) and following the general procedure C, amide 29 (143 mg, 78% yield) 
was obtained as a yellowish solid. Column chromatography (hexane/EtOAc) gave 29 as 
a white solid (101 mg), mp  100 ̶ 101 ºC; IR (ATR) ν: 636, 747, 791, 829, 866, 891, 
977, 1026, 1083, 1124, 1207, 1243, 1266, 1346, 1382, 1442, 1625, 2857, 2925 cm-1; 
1H-NMR (400 MHz, CDCl3) δ: 0.84 [dd, J = 10.8 Hz, J’ = 4.8 Hz, 4 H, 6’(13’)-H2 or 
11’(12’)-H2], 0.93 (d, J = 3.6 Hz, 12 H, 7’(8’)-CH3 and 9’(10’)-CH3], 1.18-1.34 
[complex signal, 3 H, 3(5)-Hax and 4-Hax], 1.52 (m, 2 H, 2(6)-Hax), 1.64-1.84 [complex 
signal, 9 H, 3(5)-Heq, 4-Heq, 2(6)-Hax and 11’(12’)-H2 or 6’(13’)-H2], 2.35 (tt, 1 H, J = 
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11.6 Hz, J’ = 3.2 Hz, 1 H, 1-H), 3.59 (d, J = 15.6 Hz, 4 H, 2’-H2 and 4’-H2); 13C-NMR 
(100.5 MHz, CDCl3) δ: 15.5 [CH3, H3C-C7’(8’) or H3C-C9’(10’)], 15.6 [CH3, H3C-
C9’(10’) or H3C-C7’(8’)], 25.8 (CH2, C4), 25.9 [CH2, C3(5)], 29.0 [CH2, C2(6)], 42.4 
(CH, C1), 42,9 [CH2, C6’(13’) or C11’(12’)], 43.0 [CH2, C11’(12’) or C6’(13’)], 45.3 
[C, C7’(8’) or C9’(10’)], 45.4 [C, C9’(10’) or C7’(8’)], 47.0 (C, C1’ or C5’), 48.9 (C, 
C5’ or C1’), 51.6 [CH2, C2’ or C4’], 53.1 [CH2, C4’ or C2’], 174.6 (C, CO). Anal. 
Calcd for C23H35NO: C 80.88, H 10.33, N 4.10. Found: 80.97, H 10.27, N 4.00. 
6.2. Molecular modeling 
Docking calculations were carried out using Glide [60], with the X-ray structure of 
human enzyme 4BB6 [61]. The geometry of each ligand was energy minimized and the 
centroid of the inhibitor cocrystalised in 4BB6 was used to generate the docking cavity 
by selecting all the residues located within 20 Å from the ligand. Between 70 and 100 
poses were generated for each ligand, and the best-scored poses (and the expected 
arrangement within the binding pocket) were chosen as starting structures for MD 
simulations.  
For each ligand-protein complex two independent 50ns MD simulations were run to 
check the consistency of the binding mode. To this end, the ligand-protein complex was 
immersed in an octahedral box of TIP3P [62] water molecules and sodium ions were 
added to neutralize the system. The force field ff99SBildn [63-64] was used for the 
protein parameters, and RESP charges at the HF/6-31G (d) together with the gaff [65] 
force field were used to for the ligand and NADP parameters. All systems were refined 
using a three-step energy minimization procedure (involving first hydrogen atoms, then 
water molecules, and finally the whole system) and a six-step equilibration (heating the 
system from 0 K to 300 K in 6 steps of 20 ps, the first, 50 ps the next four, and 5 ns the 
last one). 
6.3. Human 11β-HSD1 in vitro enzyme inhibition assay 
11β-HSD1 activity was determined in mixed sex, human liver microsomes (Celsis In-
vitro Technologies) by measuring the conversion of 3H-cortisone to 3H-cortisol.  
Percentage inhibition was determined relative to a no inhibitor control. 5 µg of human 
liver microsomes were pre-incubated at 37°C for 15 min with inhibitor and 1 mM 
NADPH in a final volume of 90 µL Krebs buffer. 10 µL of 200 nM 3H-cortisone was 
then added followed by incubation at 37°C for a further 30 min.  The assay was 
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terminated by rapid freezing on dry ice and 3H-cortisone to 3H-cortisol conversion 
determined in 50 µL of the defrosted reaction by capturing liberated 3H-cortisol on anti-
cortisol (HyTest Ltd)-coated scintillation proximity assay beads (protein A-coated YSi, 
GE Healthcare). A nanomolar 11β-HSD1 inhibitor, UE2316, was added as a positive 
control within in each set of assays. IC50 values for UE2316 were within the normal 
range across each test occasion [66]. 
6.4. Mouse 11β-HSD1 in vitro enzyme inhibition assay 
11β-HSD1 activity was determined in pooled mouse (CD-1) liver microsomes (Celsis 
In-vitro Technologies) by measuring the conversion of cortisone to cortisol by LC/MS.  
Percentage inhibition was determined relative to a no inhibitor control. 5 µg of mouse 
liver microsomes were pre-incubated at 37°C for 15 min with inhibitor and 1 mM 
NADPH in a final volume of 90 µL Krebs buffer. 10 µL of 2 µM cortisone was then 
added followed by incubation at 37°C for a further 30 min.  The assay was terminated 
by rapid freezing on dry ice and subsequent extraction with acetonitrile on thawing. 
Samples dried down under nitrogen at 65ºC and solubilised in 100 µl 70:30 H2O:ACN 
and removed to a 96-well V-bottomed plate for LC/MS analysis. Separation was carried 
out on a sunfire 150 x 2.1 mm, 3.5 µM column using a H2O:ACN gradient profile. 
Typical retention times were 2.71 min for cortisol and 2.80 min for cortisone. The peak 
area was calculated and the concentration of each compound determined from the 
calibration curve. 
6.5. Microsomal stability assay 
The microsomal stability of each compound was determined using either human or 
mouse liver microsomes (Celsis In-vitro Technologies).  Microsomes were thawed and 
diluted to a concentration of 2 mg/mL in 50 mM NaPO4 buffer pH 7.4.  Each compound 
was diluted in 4 mM NADPH (made in the phosphate buffer above) to a concentration 
of 10 µM.  Two identical incubation plates were prepared to act as a 0 minute and a 30 
minute time point assay.  30 µL of each compound dilution was added in duplicate to 
the wells of a U-bottom 96-well plate and warmed at 37˚C for approximately 5 
min.  Verapamil, lidocaine and propranolol at 10 µM concentration were utilised as 
reference compounds in this experiment.  Microsomes were also pre-warmed at 37˚C 
before the addition of 30 µL to each well of the plate resulting in a final concentration 
of 1 mg/mL.  The reaction was terminated at the appropriate time point (0 or 30 min) by 
addition of 60 µL of ice-cold 0.3 M trichloroacetic acid (TCA) per well.  The plates 
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were centrifuged for 10 min at 112 x g and the supernatant fraction transferred to a fresh 
U-bottom 96-well plate.  Plates were sealed and frozen at -20 ˚C prior to MS 
analysis.  LC-MS/MS was used to quantify the peak area response of each compound 
before and after incubation with liver microsomes using MS tune settings established 
and validated for each compound.  These peak intensity measurements were used to 
calculate the % remaining after incubation with microsomes for each hit compound. 
6.6. Cellular 11β-HSD1 enzyme inhibition assay 
The cellular 11β-HSD1 enzyme inhibition assay was performed using HEK293 cells 
stably transfected with the human 11β-HSD1 gene. Cells were incubated with substrate 
(cortisone) and product (cortisol) was determined by LC/MS. Cells were plated at 2 x 
104 cells/well  in a 96-well poly-D-lysine coated tissue culture microplate (Greiner Bio-
one) and incubated overnight at 37 ºC in 5% CO2 95% O2. Compounds to be tested were 
solubilized in 100% DMSO at 10 mM and serially diluted in water and 10% DMSO to 
final concentration of 10 µM in 10% DMSO. 10 µL of each test dilution and 10 µL of 
10% DMSO (for low and high control) were dispensed into the well of a new 96-well 
microplate (Greiner Bio-one). Medium was removed from the cell assay plate and 100 
µL of DMEM solution (containing 1% penicillin, 1% streptomycin and 300 nM 
cortisone) added to each well. Cells were incubated for 2 h at 37 ºC in 5% CO2 95% O2. 
Following incubation, medium was removed from each well into an eppendorf 
containing 500 µL of ethyl acetate, mixed by vortex and incubated at rt for 5 min. A 
calibration curve of known concentrations of cortisol in assay medium was also set up 
and added to 500 µL of ethyl acetate, vortexed and incubated as above. The supernatant 
of each eppendorf was removed to a 96-deep-well plate and dried down under liquid 
nitrogen at 65 ºC. Each well was solubilised in 100 µL 70:30 H2O:ACN and removed to 
a 96-well V-bottomed plate for LC/MS analysis. Separation was carried out on a sunfire 
150 x 2.1 mm, 3.5 µM column using a H2O:ACN gradient profile. Typical retention 
times were 2.71 min for cortisol and 2.8 min for cortisone. The peak area was calculated 
and the concentration of each compound determined from the calibration curve. 
6.7. Cellular 11β-HSD2 Enzyme Inhibition Assay 
For measurement of inhibition of 11β-HSD2, HEK293 cells stably transfected with the 
full-length gene coding for human 11β-HSD2 were used.  The protocol was the same as 
for the cellular 11β-HSD1 enzyme inhibition assay, only changing the substrate, this 
time cortisol, and the concentrations of the tested compounds, 10, 1 and 0.1 µM. 
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6.8. Parallel Artificial Membrane Permeation Assays- Blood-Brain Barrier (PAMPA-
BBB) 
To evaluate the brain penetration of the different compounds, a parallel artificial 
membrane permeation assay for blood-brain barrier was used, following the method 
described by Di [50]. The in vitro permeability (Pe) of fourteen commercial drugs 
through lipid extract of porcine brain membrane together with the test compounds were 
determined. Commercial drugs and assayed compounds were tested using a mixture of 
PBS:EtOH (70:30).  Assay validation was made by comparing the experimental 
permeability with the reported values of the commercial drugs by bibliography and 
lineal correlation between experimental and reported permeability of the fourteen 
commercial drugs using the parallel artificial membrane permeation assay was 
evaluated (y = 1.5366x -0.9672; R2=0.9382). From this equation and taking into account 
the limits established by Di et al. for BBB permeation [50],  we established the  ranges 
of permeability as  compounds of high BBB permeation  (CNS +): Pe (10-6 cm s-1) > 
5.179; compounds of low BBB permeation (CNS −): Pe (10-6 cm s-1) < 2.106 and  
compounds of uncertain BBB permeation (CNS ±): 5.179 > Pe (10-6 cm s-1) > 2.106. 
6.9. Pharmacokinetic study 
All the animal experiments were performed according to the protocols approved by the 
Animal Experimentation Ethical Committee of Universitat Autònoma de Barcelona and 
by the Animal Experimentation Commission of the Generalitat de Catalunya (Catalan 
Government). Male CD-1 mice (20-25 g) purchased from Envigo Laboratories were 
used. Compound 23 was dissolved in cyclodextrin 10% at 3 mg/mL to give a clear 
solution. After oral administration (21 mg/kg, 10 mL/Kg), blood (0.6 mL) was collected 
from cava vein using a syringe (23G needle) rinsed with 5% EDTA(K2) at 0, 0.5, 1, 3, 5 
and 24 (3 animals/point). Each blood sample was immediately transferred to a tube 
containing 40 µL of water with 5% EDTA. Blood samples were centrifuged at 10000 g 
for 5 minutes and plasma samples were stored at −20 °C until analysis of compound 
concentration by UPLC-MS/MS. Brains were transcardially perfused with 10 mL of 
saline, removed, frozen in liquid N2 and stored at −80 °C until analysis of the compound 
concentration by UPLC-MS/MS. 
6.10. In vivo study 
6.10.1. Animals. 
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SAMP8 mice 12 months old (n=12) were randomized in 2 experimental groups (control, 
n=4; treated, n=8), and additional group 2 months old (n=4) were planned as a young 
population. Mice were used with free access to food and water, under standard 
temperature conditions (22 ± 2°C) and 12-h:12-h light-dark cycles (300 lx/0 lx). 
Compound 23 was administered dissolved in tap water and PEG400 (2% final 
concentration) yielding a dose of 21 mpk for 4 weeks. The dose was selected based on 
the IC50 value of 23 and our previous expertise in in vivo studies with other 11β-HSD1 
inhibitors [20-21]. To maintain the correct dose along the treatment period, once a week 
the weight of the animals and the quantity of water that they drank were measured. 
Therefore, we adjusted the concentration (mg/mL) of the compound 23 in the drink 
bottle to achieve the correct dose of compound (mpk) to be administered to mice. 
Studies were performed in accordance with the institutional guidelines for the care and 
use of laboratory animals established by the Ethical Committee for Animal 
Experimentation at the University of Barcelona. 
6.10.2. Novel Object Recognition Test (NORT). 
The test was conducted in a 90-degree, two-arm, 25-cm-long, 20-cm-high maze. Light 
intensity in the middle of the field was 30 lux. The objects to be discriminated were 
plastic figures (object A, 5.25-cm-high, and object B, 4.75-cm-high). First, mice were 
individually habituated to the apparatus for 10 min per day during 3 days. On day 4, 
they were submitted to a 10-min acquisition trial (first trial), during which they were 
placed in the maze in the presence of two identical novel objects (A+A or B+B) placed 
at the end of each arm. A 10-min retention trial (second trial) occurred 2 h (short term 
memory) or 24 h (long term memory) later. During this second trial, objects A and B 
were placed in the maze, and the times that the animal took to explore the new object 
(tn) and the old object (to) were recorded. A Discrimination index (DI) was defined as 
(tn-to)/(tn+to). In order to avoid object preference biases, objects A and B were 
counterbalanced so that one half of the animals in each experimental group were first 
exposed to object A and then to object B, whereas the other one half first saw object B 
and then object A was presented. The maze, the surface, and the objects were cleaned 
with 96º ethanol between the animals’ trials so as to eliminate olfactory cues. 
6.10.3. Brain isolation and Western blot analysis. 
Mice were euthanized 1 day after the last NORT trial was conducted, and brain quickly 
removed from the skull. Hippocampus were dissected and frozen in powdered dry ice 
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and maintained at −80 °C for further use. Tissue samples were homogenized in lysis 
buffer containing phosphatase and protease inhibitors (Cocktail II, Sigma), and cytosol 
and nuclear fractions were obtained as described elsewhere. Protein concentration was 
determined by the Bradford method. 20 µg of protein were separated by Sodium 
dodecyl sulfate-Polyacrylamide gel electrophoresis (SDS-PAGE) (8-15%) and 
transferred onto Polyvinylidene diflouride (PVDF) membranes (Millipore). The 
membranes were blocked in 5% non-fat milk in Tris-buffered saline containing 0.1% 
Tween 20 (TBS-T) for 1 h at rt, followed by overnight incubation at 4°C with primary 
antibodies against PSD95 (1:1,000, ab18258/Abcam), IDE (1:1,000, ab32216/Abcam) 
and APP C-Terminal Fragment (1:1,000, C1/6.1/Covance) diluted in TBS-T and 5% 
bovine serum albumin (BSA). GAPDH (1:2,000, Millipore) was used as a control 
protein charge. Membranes were then washed and incubated with secondary antibodies 
for 1 h at rt. Immunoreactive proteins were visualized utilizing an Enhanced 
chemiluminescence-based detection kit (ECL kit; Millipore) and digital images were 
acquired employing a ChemiDoc XRS+System (BioRad). Band intensities were 
quantified by densitometric analysis using Image Lab software (BioRad) and values 
were normalized to GAPDH. 
6.10.4. RNA extraction and gene expression determination. 
Total RNA isolation was carried out by means of Trizol reagent following the 
manufacturer’s instructions. RNA content in the samples was measured at 260 nm, and 
sample purity was determined by the A260/280 ratio in a NanoDrop™ ND-1000 
(Thermo Scientific). Samples were also tested in an Agilent 2100B Bioanalyzer 
(Agilent Technologies) to determine the RNA integrity number. Reverse transcription-
Polymerase chain reaction (RT-PCR) was performed as follows: 2 µg of messenger 
RNA (mRNA) was reverse-transcribed using the High Capacity complementary DNA 
(cDNA) Reverse Transcription kit (Applied Biosystems). Real-time quantitative PCR 
(qPCR) was utilized to quantify the mRNA expression of inflammatory genes 
Interleukin 6 (IL-6) and inducible nitric oxide synthase (iNOS). Normalization of 
expression levels was performed with Actin for SYBER Green. The primers were as 
follows: for IL-6, forward 5'-ATCCAGTTGCCTTCTTGGGACTGA-3' and reverse 5'-
TAAGCCTCCGACTTGTGAAGTGGT-3', for iNOS, forward 5'- 
GGCAGCCTGTGAGACCTTTG-3' and reverse 5'- GAAGCGTTTCGGGATCTGAA-
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3', for Actin, forward 5'-CAACGAGCGGTTCCGAT-3' and reverse 5'-
GCCACAGGTTCCATACCCA-3'. 
Real-time PCR was performed on the Step One Plus Detection System (Applied 
Biosystems) employing the SYBR Green PCR Master Mix (Applied Biosystems). Each 
reaction mixture contained 7.5 µL of cDNA, whose concentration was 2 µg/µL, 0.75 µL 
of each primer (whose concentration was 100 nM), and 7.5 µL of SYBR Green PCR 
Master Mix (2X). 
Data were analysed utilizing the comparative Cycle threshold (Ct) method (∆∆Ct), 
where the actin transcript level was utilized to normalize differences in sample loading 
and preparation. Each sample (n = 4-8) was analysed in triplicate, and the results 
represented the n-fold difference of transcript levels among different samples. 
6.10.5. Data analysis. 
Data are expressed as the mean ± Standard Error of the Mean (SEM). Data analysis was 
conducted using GraphPad Prism® ver. 6 statistical software. Means were compared 
with one-way Analysis of Variance (ANOVA) and Tukey post hoc analysis. 
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